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Abstract
Infective endocarditis is an infectious disease that affects the valves of the
heart. Injection drug use is currently a leading risk factor among patients with endocarditis.
We conducted a prospective study using data from hospital chart records among patients with
endocarditis in London, Ontario, which has a relatively high prevalence of people who inject
drugs to assess the severity of the issue and the major risk factors of mortality pertaining to
this population. This study had a sample size of 353 and included a review of the incidence
of admissions of endocarditis, as well as a survival analysis, using both univariate and
multivariate methods. We found the incidence to be rising among both people who inject
drugs and those who do not. In the total group, the use of injection drugs (HR: 2.50, 95%
C.I. 1.41 to 4.34), age (HR: 1.03 per year, 95% C.I. 1.01 to 1.05), methicillin resistant
staphylococcus aureus infection (HR: 3.23, 95% C.I. 1.79 to 5.84) and methicillin sensitive
staphylococcus aureus (HR:1.74, 95% C.I. 1.05 to 2.87) infection were shown to be
significantly associated with all-cause mortality. With the ongoing proliferation of injection
drug use, additional harm reduction strategies to further reduce the incidence and impact of
endocarditis among people who inject drugs is important.
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Infective endocarditis, people who inject drugs, injection drug use, IDU-associated infective
endocarditis, incidence analysis, survival analysis.
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Chapter 1

1

Introduction
The use of injection drugs and the adverse health outcomes associated with them has

become a growing concern in developed countries over the past few decades. Mainstream
media has been effective in highlighting the repercussions associated with what is referred to
as the “opioid crisis” in North America and around the world. More specifically, addictions
and overdoses from highly potent opioids such as fentanyl have become alarming realities
that are regularly discussed in mainstream sources. The death toll due to opioid overdose has
continued to rise, taking 2,458 Canadian lives in 2016 (GoC, 01/2018). In the United States,
the number of overdose deaths attributable to prescription opioid misuse from 1999 to 2015
is over 183,000 according to the Centers for Disease Control and Prevention (CDC,
08/2017).
In the US, publications have suggested that the rates of injection drug use have been
decreasing in the past couple decades (Roy et al, 2016), which at face value seems like good
news. While the total number of people who inject drugs appear to be decreasing, the most
at-risk population has changed as the number of people who inject drugs (PWID) aged 15-29
are increasing (Roy et al, 2016). This is aligned with the findings of Wurcel et al (2016) who
used the Health Care and Utilization Project National Inpatient Sample (HCUP-NIS) dataset
to find proportion of IE hospitalizations from injection drug use (IDU) associated IE
increased from 7% in 2000 to 12.1% in 2013 (Wurcel et al, 2016). They found significant
increases of IDU-IE hospitalizations among 15- to 34-year-olds (27.1%–42.0%; P < .001)
and among whites (40.2%–68.9%; P < .001). The tendency for young individuals to be at an
1

elevated risk may represent a significant Public Health issue, although there is unfortunately
no available data to predict national trends in Canada (Roy et al, 2016). In 2001, Health
Canada estimated there to be 100,000 PWID in Canada. A decade later, the Public Health
Agency of Canada (PHAC) estimated the population grew to approximated 113,000,
although no trends can be reliably predicted from these estimates (Roy et al, 2016). Most
research targeting populations of PWID is cross-sectional by nature as there are commonly
attrition issues that prevent long-term prospective cohort studies.
People who inject drugs (PWID) may have one or several comorbidities including,
but not limited to, HCV, HIV, diabetes, psychiatric disorders, and the focus of this thesis,
Infective Endocarditis (IE). I-track, a surveillance system that tracks HIV/HCV prevalence
among PWID, has been successful in uncovering the high lifetime prevalence of chronic
diseases such as HIV and Hepatitis C, with proportions reaching 5.5% and 79.1%,
respectively in London, Ontario (MLSU, 2013). This is compared to I-tracks Canadian
national averages of 11% and 68% (MLHU, 2013), which shows London to have a lower
incidence of HIV (5.5% less) and higher incidence of Hepatitis C (11.1% greater) relative to
national averages. Incidence of HCV infection may be used as a surrogate for unsafe
injection practices (Brooks, 2016), as HCV is much more infectious than HIV and is most
often associated with injection drug use (Brooks, 2016). In the United State, more than 70%
of new HCV infections since 2006 have unsafe injection practices as the most significant risk
factor (Zibbell, 2015). The high prevalence of HCV indicates that London, Ontario may be a
fertile ground for infectious diseases, and the low proportion of HIV indicates a high
susceptibility to future HIV epidemics. In a vulnerability assessment conducted by Van
Handel et al (2016), their models suggested that prescription opioid sales, per capita income,
unemployment, and Caucasian ethnicity to be four of the six indicators for at-risk
2

populations, or populations with the greatest potential for an infectious disease outbreak (Van
Handel et al, 2016). Although the Ontario Southwest LHIN (Local Health Integration
Network) has lower total opioid prescriptions per 10,000 persons in comparison to the
provincial average (1,403 vs. 1,431), the prescription rates of Hydromorphone Contin, an
opioid that is commonly used by PWID in London, are higher per 10,000 than the provincial
average (214 vs. 168). With regards to unemployment, although the unemployment rate is
not particularly low London has an employment rate of 57% indicating 43% of the population
is either unemployed (6.2%) or not in the labour force (38.8%) (StatCan, 2018). The
unemployment rate is generally used to explain the percentage of people that are not
working. This suggests that although the unemployment figure specifically is not high, the
number of people without employment is. Both the mean and median income of individuals
in London, Ontario aged 15 years or greater ($39,229 and $29,478, respectively) are lower
than both the provincial ($42,264 and $30,526) and national ($40,650 and $29,878)
statistics. Lastly, London is disproportionately Caucasian compared to provincial averages
as only 16% of the population is a visible minority (MacTaggart et al, 2013). Despite the
many contributions made by publications such as the I-track study mentioned earlier, there
remains no publicly available data on relatively acute, potentially fatal diseases such as
Infective Endocarditis, nor on the total number of at risk PWID. The data does suggest,
however, that London, Ontario represents a fertile ground for infectious disease outbreaks in
the PWID population.
IE is widely recognized as a major issue among PWID and presents a major problem
as the recurrence rates following treatment remain high (Saydain et al, 2010). Infective
Endocarditis (IE) is an infection of the heart valve and requires a syndrome diagnosis,
meaning a collection of signs and symptoms to classify a patient as “possible” or “definite”
3

IE, most commonly via the modified Duke Criteria (Li et al, 2000). Many studies that
explore first-episode infective endocarditis find PWID to have more favorable outcomes than
non-injection-drug-users (non-PWIDs) (Ruotsalainen et al, 2006), as they tend to have rightsided IE which has a more promising prognosis (Cahill et al, 2016). PWID patients tend to
be much younger, have higher rates of readmission, develop recurrent IE and therefore have
poor long-term prognoses despite their favourable short-term prognosis following their firstepisode of IE (Rosenthal et al, 2016). The young age is attributable to the lifestyle induced
infective endocarditis. Since the causal lifestyle often remains upon leaving the hospital,
readmissions for recurrent IE are common.
The mechanism behind PWID-associated IE is twofold in that it requires a blemished
heart valve as well as the presence of bacteria in the blood. There are nuances to both
conditions, although the most common explanation found in the literature is that PWID inject
sharp particulate matter directly into the bloodstream, scratching and blemishing the tricuspid
valve as the blood returns to the heart (Frontera et al, 2000). PWID-associated IE is
generally associated with right-sided endocarditis for this reason.
In non-PWIDs, left-sided infective endocarditis is found to be more
common. Patients also tend to be much older, display pre-existing heart complications such
as congenital heart disease or have prosthetic valves. As such, their pathophysiology is
different, and their prognosis is worse upon first admission, although they have lower rates of
readmission than PWID.

4

Chapter 2

2

Literature Review and Objectives
This review begins with definitions and inclusion criteria for the diagnosis of

infective endocarditis. Next, there is a review of injection drug use, infectious disease in
general, and the relationships between them, which come together to form the population
focused on in this thesis: patients with infective endocarditis (an infectious disease) that use
injection drugs. Then follows the incidence and survival of patients diagnosed with infective
endocarditis. The mechanisms and pathogenesis of infective endocarditis are also reviewed,
as well as injection drug use in London, Ontario. Lastly, this section includes study
objectives and rationales.

2.1 Definition and Diagnostic Criteria for IE
Infective Endocarditis (IE) is an infectious disease affecting the heart valve. Infective
is alluding to the transmissible nature of the disease, endo refers to the endothelium, or the
single layer of cells lining the blood vessels within the body (Félétou, 2011), cardium refers
to the heart, and itis indicating inflammation. Infective Endocarditis is thereby an infectious
disease characterized by bacterial vegetations that accumulate on the heart valve in response
to valvular endothelial damage.
Infective Endocarditis is clinically diagnosed via the modified Duke Criteria. This is
a syndrome diagnosis (Li et al, 2000), meaning a collection of signs and symptoms that in
5

conjunction with one another are indicative of “possible” or “definite” endocarditis. The
original Duke Criteria (Durack et al, 1994) demonstrated a high sensitivity and specificity
(Cecchi et al, 1997) (Li et al, 2000), although the clinical diagnosis of “possible IE” was
frequently criticized. A “possible IE” diagnosis required the patient not meet “rejected IE”
requirements and have one minor criterion present was suggested to be too inclusive (Li et al,
2000). To “raise the diagnostic floor” on possible IE cases (Li et al, 2000) and decrease the
type I error rate, Li et al (2000) proposed a modification to “possible IE” diagnostic
criteria. The Modified Duke Criteria defines “definite” endocarditis as presenting two major
criteria, whereas “possible” IE occurs when either one major and one minor criteria, or three
minor criteria are present (Li et al, 2000). Major Criteria include bacteremia known to cause
IE, echocardiographic evidence such as vegetations, and new valvular regurgitation or leaky
heart valves. Minor Criteria include predisposing conditions such as intravenous drug use
and diabetes, vascular phenomena, immune phenomena, fever, and blood cultures that are not
belonging to the Duke Major Criteria (Li et al, 2000). The criteria have been arranged in a
table by Li et al (2000) and is included in the appendix (table 1).

2.2 Infectious Diseases and Injection Drug Use
People who use injection drugs are at an elevated risk of death from acute and chronic
infectious diseases as well as drug overdose in comparison to those who do not inject drugs
(Mathers et al, 2012). In a systematic review conducted by the World Health Organization
(WHO), standardized mortality ratios (SMRs) were used to assess the excess mortality that
has resulted among PWID. SMR is a summary index ratio that calculates the relationship
6

between the observed and expected values based on crude counts (Fleiss et al, 2004) or ageand sex-specific rates in a standard population (NM-IBIS, 2017). An SMR may be
calculated for all-cause mortality or for mortality attributable to a particular cause in a given
population, and the expected number of deaths. In this case, excess mortality was calculated
with death rate among PWID in terms of person-years as the numerator, and death rate in the
general population as the denominator. Researchers at the WHO calculated an SMR of 11.19
(95% C.I. 3.58 to 18.80) (Mathers et al, 2012) indicating that all else being equal, PWID in
North America are at an 11.19 times greater risk of mortality than non-PWIDs. Among
PWID, crude global estimates found that all-cause mortality was three times greater (3.15,
95% C.I. 2.76 to 3.50) and risk of drug overdose death was two times greater (1.99, 95% C.I.
1.31 to 3.04) for those diagnosed with HIV compared to those without (Mathers et al, 2012).
Overdoses are responsible for the most fatalities among PWID in Europe and North
America (Copeland et al, 2004) although this may not be the case universally. An analysis of
a Vancouver inner-city cohort by Deans et al (2013) suggests that infection may have
surpassed overdose with regards to mortality (Deans et al, 2013). Of the 374 deaths that
occurred among the 2913 participants, 97 (25.9%) were infections, and 37 (9.9%) were from
external causes which included accidents, assault and intentional self-harm (Deans et al,
2013). Excess mortality was highest among participants infected with HCV, HIV, or both
(Deans et al, 2013), suggesting that infectious diseases associated with injection drug use
may be more significant relative to overdose in Canada than larger American studies
suggest.
There are many overlapping risk factors among various infectious diseases which
why HCV, which is approximately 10 times more infectious than HIV (Budd and Robertson,
2005), is used as a surrogate indicator for the fertility of a given population for infectious
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disease epidemics (Zibbell et al, 2015). In reviewing the health consequences associated
with injection drug use, blood borne viral infections tend to be the most discussed,
particularly HCV and HIV, although many PWID are more familiar with bacterial infections
such as cellulitis and, less commonly, Infective Endocarditis. While blood borne viruses
require sharing needles or reusing paraphernalia to make transmission of the virus possible,
bacterial infections do not. The bacteria most commonly found among PWID with infective
endocarditis are common, even among healthy individuals (Ryan, 2003).
In North America, S. aureus is present in over half of the infective endocarditis cases
(Slipczuk et al, 2013). Furthermore, S. aureus and streptococcus species together account for
80% of first-episode infective endocarditis cases (Hoen, 2013). The mouth, specifically the
buccal and tongue mucosa, are home to many streptococci species which can be transferred
by the hands to drug paraphernalia or the drugs themselves. S. aureus is present in 25-30%
of healthy people at any given time and can be spread from hand-to-nose contact (Ryan,
2003). Even with antiseptic washing is difficult to eliminate all potentially pathogenic
microbes from the skin (Ryan, 2003).

2.3 Incidence and Survival of Patients with IE
Studies vary in their incidence estimation for infective endocarditis, with large
reviews reporting incidence rates of 2.4 to 11.6 per 100,000 person-years (Klein et al, 2016),
and proportions 3-10 per 100,000 people (Cahill et al, 2016). Of these, hospital-acquired
infective endocarditis has accounted for 25-30% of the cases within recent cohorts, with the
average patient age being greater than 70 years (Cahill et al, 2016). Degenerative valve
8

disease, particularly that of the mitral valve, is shown to be present in approximately 30% of
cases (Klein et al, 2016). These statistics are for the population at large, although the
epidemiological findings for PWID with PWID-associated Infective Endocarditis suggest a
greater incidence, a younger patient age (Shrestha et al, 2015)(Tung et al, 2015), a more
benign first-episode of IE (palepu et al, 2002), and less hospital-acquired infection (Wilson et
al, 2002) as endocarditis is acquired via the injection drug use itself. In a prospective study
of IE among PWID in New York City between February, 1988 and March, 1989, Wilson et
al (2002) found an incidence of 7.1 cases per 1000 person-years (95% C.I 5.88 to 8.51). That
is approximately 700 cases per 100,000 person-years, compared to the previously mentioned
incidence of 2.4 to 11.6 cases per 100,000 in the general population. The 95% confidence
intervals suggest a 60- to nearly 300-fold increased incidence of IE for PWID relative to the
total population, which includes the PWID themselves.
The population of PWID is not a homogeneous group, as is revealed by stratifying
based on comorbidities. Immunosuppression, or more specifically a CD4 count less than
400, among HIV-seropositive PWID further increases the risks of infection and death in
general (Wilson et al, 2002). This is consistent with more recent data in Vancouver, British
Columbia (Deans et al, 2013). The incidence of HIV-related deaths in this cohort was 46
(95% C.I. 37 to 58) per 10,000 person-years, higher than drug-related and liver-related
deaths, combined (Deans et al, 2013).
The concerns regarding incidence are a function of the morbidity and mortality
associated with the disease. With regards to survival metrics, American studies have shown
Infective Endocarditis carries a 16% in-hospital mortality rate for the population at
large. Wallace et al (2002) continued to follow their cohort of patients for another 6 months
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following discharge to determine a 6-month mortality rate of 27% (Wallace et al, 2002). In a
Belgian prospective study, the six-month mortality was 22% (Hill et al, 2007).
When comparing the survival between PWID and non-PWID with IE, a multinational
prospective cohort (Murdoch et al, 2009) found that the in-hospital mortality for PWID
without intracardiac devices was 9.7%, whereas non-injection drug users were 17.1%, and
the entire cohort was 17.7% (as it included patients with intracardiac devices). In a regional
study from British Columbia, PWID-associated IE and non-PWID-associated IE were
compared, revealing that the mean age for PWID was 38.3 +/- 8.2 years, compared to 70.7
+/- 13.9 years with non-PWIDs (Tung et al, 2014). The authors also mentioned that “there
was a trend toward lower inpatient mortality” among PWID which they attributed to
increased operations (Tung et al, 2014). These studies highlight the “favourable” prognoses
for PWID with IE are likely attributable to the differences in age and, as shown in other
research (Shrestha et al, 2015), the short follow-up period. Shrestha et al (2015) followed up
for a longer period and found that the 90-day survival free of operation (no mortality, no
operation) corresponded to a hazard ratio of 0.38 (95% C.I. 0.05 to 3.07) for PWID,
indicating a non-significant survival trend that favoured PWID. The cumulative incidence of
mortality specifically, as opposed to the combined mortality and reoperation, was much
lower for PWID at 90 days. At the 1000-day mark however, the cumulative incidence of
mortality was very similar for both PWID and non-PWIDs at just over 20%. “The ultimate
survival was no different (for non-PWIDs) than that of patients who did not inject drugs”
(Shrestha et al, 2015). This is statistically demonstrated via a log-rank test for overall
survival which produced a probability value of 0.57, indicating there was no difference in
overall survival between PWID and non-PWIDs (Shrestha et al, 2015). In conclusion, the inhospital survival of patients with Infective Endocarditis is consistently between 16-19%, with
10

PWID demonstrating much lower short-term mortality rates due to their young age relative to
non-PWIDs, although the 5-year mortality rate is similar for both groups.
These studies on survival outcomes amongst patients with IE have also shed light on
which patient characteristics are most commonly associated with both favorable and
unfavourable patient outcomes. Using multivariable regressions and bootstrap modelling,
Murdoch et al (2009) isolated variables that can demonstrate associations with in-hospital
mortality. These variables are mentioned below, with a rationale provided by other research
into the pathophysiology of endocarditis and further statistics wherever possible:
a.

Age in 10-year intervals [OR: 1.30 (95% C.I. 1.17 to 1.46)] (Murdoch et al, 2009)

A decrease in immune function is recognized as a property of aging, as elderly individuals do
not respond as effectively to unfamiliar antigens compared to younger populations
(Montecino-Rodriquez et al, 2013).
b. prosthetic valve endocarditis [OR: 1.47 (1.13 to 1.90)] (Murdoch et al, 2009)
Bacteria associated with infective endocarditis contain surface adhesins that bind to
mechanical structures, producing a biofilm (Nataloni et al, 2010) that contributes directly to
infective endocarditis (Holland et al, 2017). This biofilm prevents host defenses from
destroying the potential pathogen (Nataloni et al, 2010) and protects against antimicrobial
treatment, permitting “device-associated vegetation propagation” (Holland et al, 2017).
c. Staphylococcus aureus infection [OR: 1.54 (1.14 to 2.08)] (Murdoch et al, 2009)
These finding are consistent with results from Chu et al (2004) [OR: 2.06 (1.01 to
4.20)]. The associations may be attributable to S. aureus containing proteins that allow for
greater adherence to valve tissues relative to other bacteria (Frontera et al, 2000). The
adhesins in S. aureus have also been shown to rapidly coat intracardiac devices (Frontera et
al, 2000), exacerbating the effects of the biofilm mentioned previously.
11

d. Mitral valve vegetation [OR: 1.34 (1.06 to 1.68)] (Murdoch et al, 2009)
The mitral valve is in the left side of the heart, separating the left atrium and ventricle and is
the most common site of IE amongst the general population, with three leading mechanisms
to explain this phenomenon. The left side of the heart contains higher pressures and more
turbulent blood flow, left sided blood is more richly oxygenated, and congenital/acquired
lesions are more common on the left side of the heart (Frontera et al, 2000).
e. Diabetes mellitus [OR: 1.28 (0.88 to 1.86)] (Murdoch et al, 2009)
Diabetes being significantly associated with in-hospital mortality was also shown in a study
by Chu et al (2004) [OR: 2.48 (1.24 to 4.96)] and the bootstrap model by Murdoch et al
(2009) [OR: 1.45 (1.08 to 1.85)]. It has been suggested that the adverse effects of
hyperglycemia on a patient’s immune function may be responsible for the unfavourable
outcomes associated with diabetes (Chu et al, 2004).
Other risk factors associated with increased short-term mortality include paravascular
complications, embolic events, pulmonary edemas, and APACHE II score, while surgery and
viridans streptococcal infection were associated with reduced odds of mortality (Murdoch et
al, 2009).

2.4 Risks associated with Injection Drug Use
With regards to PWID-associated Infective Endocarditis, there are indirect effects
that extend beyond the direct effects caused by particulate matter blemishing the valves of
the heart. Indirect effects include vasoconstriction and increased blood pressure, damage to
the endothelial cells lining the blood vessels (referred to as intimal damage), formation of
blood clots, and generally decreased immune function of PWID (Tahamtan et al, 2016)
12

(Frontera, 2000). Indirect effects differ depending on whether the PWID uses opioids such
as hydromorphone or stimulants such as methamphetamine and cocaine. Different drugs will
be explained below their respective sequence.
In a qualitative analysis by Roy et al (2011), public health concerns surrounding the
injection of prescription opioids were uncovered within the cohort of participants in the
study. With regards to Hydromorph Contin, there are reasons why it is preferable over
heroin. “Hydros”, as they are referred to, and Dilaudid are not distributed by criminal
organization as is the case with cocaine and heroin. They are easy to find, inexpensive, and
of uniform quality (Roy et al, 2011). Prices in Montreal begin at less than $10 for a 1mg
Dilaudid, resulting in a relatively low barrier to entry. There are however new patterns of
risk taking that are being uncovered because of the growing popularity of prescription
opioids. Firstly, there are many more daily injections with prescription opioids (Roy et al,
2011). Due to the high accessibility, users will often use lower doses more frequently, rather
than save for a larger dose that will last a longer period. If a larger capsule such as a 30mg
Hydromorphone Contin (“red rocket”) is purchased, the user must use more water to draw
out the medicine and as such, there may be multiple injections in one sitting. In this
circumstance, it is common to use the same needle to aspirate each time. The leftover
residue, referred to as a “wash”, may then be given away or sold, in which case a potentially
contaminated cooker/filter is being reused, despite the efforts to never share equipment by
the users (Roy et al, 2011).

Hydromorph Contin may be consumed orally, as is intended,

and injected.
There are immunomodulatory effects that vary depending on the particular opioid
being consumed. Morphine and oxycodone are considered immunosuppressive, as opposed
to hydromorphone and codeine which are not considered immunosuppressive (Plein et al,
13

2017). In another review by Tahamtan et al (2016), they discussed both in vivo and in vitro
studies that suggest opioids have the potential to impair host immune response and increase
risks of exposure, although they did not differentiate between opioids. Opioids have also
been shown to suppress intestinal immune function by increasing gut barrier permeability
(Plein et al, 2017) (Tahamtan et al, 2016), potentially leading to bacteremia despite sterile
injection practices. Lastly, studies have shown withdrawal-induced immunosuppression
effects can be strong (Roy et al, 2011), which may be a daily occurrence for many
PWID. The magnitude of effect of these indirect risks associated with opioids is still largely
unknown.
In a review by Salamanca et al (2015), it was suggested that a major risk associated
with methamphetamine consumption are the devastating effects on host immunity
(Salamanca et al, 2015), which may predispose PWID to infectious diseases by impairing the
user’s immune system from fighting it off. Methamphetamine use is also associated with
enhanced sexual pleasure and unsafe sexual practices, thereby increasing the risks of
contracting sexually transmitted infectious diseases such as HIV (Salamanca et al, 2015).
This risk may be exacerbated by the sharing of drug paraphernalia and unsafe injection
practices such as the “shake-and-bake” method to dissolve the drug into water for
injection. Like any disinhibiting psychoactive drug, the decisions made under the influence
of the substance may be more consequential than the substance itself.
Among stimulant users (cocaine, methamphetamine, Ritalin, etc.), pulmonary
hypertension, or increased blood pressure in the vasculature around the lungs, places stress
on the heart and exposes individuals to acute increases in pressure gradients specifically
affecting the pulmonary and mitral valves (left side of the heart) (Frontera,
2000). Pulmonary Hypertension is typically a chronic disease (Shah, 2012) which increases
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the risk of left-sided infective endocarditis regardless of PWID history. This places PWID
within an at-risk population for left-sided, as well as the previously discussed right-sided,
infective endocarditis.

2.5 Mechanism and Pathogenesis of IE among general
population and PWID
Historically, rheumatic heart disease (RHD), an acute or chronic cardiac
inflammatory disease caused by group A streptococci that damages the valves of the heart
(Marijon et al, 2012), has caused most infective endocarditis cases. This is still the case in
low-income countries, although in higher-income countries the improved living standards
and accessibility to antibiotics has decreased the prevalence of RHD (Thanavaro, 2014).
Today, some of the major risk factors include congenital heart disease, degenerative heart
disease, diabetes, cancer, and intracardiac devices (Thanavaro, 2014) (Cahill, 2016). These
risk factors are associated with predominantly left-sided, specifically the mitral or aortic
valve, infective endocarditis (Frontera et al, 2000). In a review by Frontera et al (2000), leftsided IE is attributable to 3 factors. First, higher pressure exerted by the left side of the heart
produces a relatively turbulent flow in comparison to the right side, potentially leading to
damage of the mitral and aortic valves. Second, the left atrium only contains oxygenated
blood coming from the lungs which is more favorable for bacterial proliferation. Lastly,
congenital and acquired lesions are more common on the left side of the heart (Frontera,
2000). None of these three factors are a function of lifestyle and preventative interventions
are not feasible. The focus of the thesis, intravenous drug use, is a risk factor (Shrestha et al,
2015) that is overwhelmingly associated with right-sided IE.
15

Epidemiological data collected by Cahill and Prendergast (2016) found that the
average patient age has nearly doubled since the 1980’s (Cahill et al, 2016). This is largely
attributable to an increased frequency of cardiac implantable devices, which are a risk factor
for IE based on the Duke Criteria (Thanavaro, 2014). The rising age was also noted in a
review of hospital-based studies by Slipczuk et al (2013), with a mean age in the 1980s of
45.3 years (95% C.I. 40.2 to 50.5) and a mean age in the 2000’s of 57.2 years (95% C.I. 54.7
to 59.7) (Slipczuk et al, 2013). Slipczuk et al (2013) also found non-significant increases in
the frequency of prosthetic valve IE, which may explain a discrepancy in their findings
compared with Thanavaro et al (2014). While infective endocarditis continues to occur later
and later in life among patients with congenital heart defects, populations of PWID are facing
a more disturbing reality.
With regards to people who inject drugs, risk factors are largely attributable to the
injection of drugs themselves, as opposed to congenital heart conditions. Native-valve
infective endocarditis occurs on damaged valvular endothelium, or the single layer of cells
lining the heart valves, which permits bacterial colonization with “specific adherence
properties” (Hoen, 2013). These properties are found among streptococci and staphylococci
bacteria, and these microorganisms are most commonly isolated from patients with firstepisode, native-valve infective endocarditis. These microorganisms have been shown to
account for 80% of cases of IE (Hoen, 2013).
IE vegetations may occur via bacterial proliferation on the heart valve and/or by the
endogenous clotting process that is meant to repair the blemished valve, both of which
require a blemished valve. Once an endothelial lesion occurs, the clotting process for
damaged tissues requires fibrin, a fibrous mesh to impede blood flow (Shah, 2012), and
platelets which form the origin of the vegetation that commonly characterizes infective
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endocarditis (Klein et al, 2016). This damage may be a result of intravenous injection of
solid particles, which has a direct effect on cardiac valves, particularly the right-sided
tricuspid valve, via “repetitive bombardment with particulate matter that is present in injected
material” (Frontera et al, 2000). In a lab experiment conducted by Laura Ball, a medical
student at Western university, it was found that Hydromorph Contin that has been prepared
for injection contains particulate matter greater than 5 microns, even when using a filter to
aspirate. When drawing only sterile water through a pressed cotton filter with a needle, the
cotton filters themselves have been found within injectate which could theoretically scrape
and physically damage the endothelium. These images and explanatory captions can be
found within the appendix (figures 1 and 2).
The pathophysiology of IE begins with endothelial damage, but also requires
bacteremia, or the presence of bacteria in the blood, to cause an infection. Non-hospital
acquired bacterial exposures may include non-sterile injection practices and/or contaminated
drugs themselves. Non-sterile injection practices include, but are not limited to, failing to
cleanse the skin with alcohol swabs before injection, using non-sterile tap water as a solvent,
reusing/sharing contaminated paraphernalia, licking needle wounds, licking needles
themselves, and handling drugs with contaminated hands (Haverkos, 1990). Unsanitary
environments may also be an issue, as 2017 study by Scheim et al (2017) found that more
than 70% of participants that participated fully in the study (n = 196) reported using injection
drugs publicly in the past 6 months due to convenience (69.5%) and homelessness (39.7%)
(Scheim et al, 2017). Non-prescription drugs such as cocaine and methamphetamine may be
exposed to bacteria in the production process and/or during packaging by street level
distributors. With regards to hydromorphone specifically, re-soaking used pill residue,
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henceforth referred to as “washes”, may create an opportunity for repeated exposures from
one contaminated pill/cooker/filter. PWID reusing filters has occurred since before the
William S. Burroughs novel Junky, which was originally published in 1953 (Burroughs,
1977), although the additional exposure of the wash residue may be driving infective
endocarditis in regions where it is popular such as South-Western Ontario (LondonMiddlesex region) (Richmond, 2017), South-Eastern Ontario (Kingston and surrounding
areas), Champlain (Ottawa and Cornwall), and many parts of Northern Ontario (Ontario
narcotics atlas, 2016). Furthermore, many injection drugs, including crystal
methamphetamine and Hydromorph contin, do not require heating to extract the medicine
into water which may have otherwise been helpful to reduce harm associated with PWID
(Haverkos, 1990).

2.6 Injection Drug Use in London
Different drugs represent unique risk profiles and pathophysiology. Most often, drug
classes are broken down into two broad groups: Opioids and stimulants. In a systematic
review by the WHO, the SMR of all-cause mortality between opioids and stimulants showed
no significant differences across studies (1.25, 95% C.I. 0.60 to 2.61) (Mathers, 2012).
Epidemiological trends in Canada have demonstrated a reduction in daily cocaine and
daily heroin injection, whereas numbers for prescription opioids and crystal
methamphetamine have “increased substantially” (Roy et al, 2016). Based on I-TRACK
survey data, this appears to be consistent with the current situation locally in London. These
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changes in drug use trends may present a new set of challenging circumstances for healthcare
providers caring for PWID.
In London, Ontario, there is over 20% more PWID who inject non-prescribed
morphine, dilaudid, and OxyContin than the national averages. With regards to crystal
methamphetamine, there were no national comparators, but 68% of participants injected
methamphetamine in the past 6 months (I-TRACK LONDON). In a preliminary analysis
drawn from a separate case-control dataset attempting to identify risk factors for IE, it was
found that PWID in London may be using more crystal methamphetamine than previously
recorded. The trend previously indicated in the research by Roy et al (2016) towards
prescription opioids and crystal methamphetamine appear to exist in London as well. Below
is a list of statistics drawn from an unpublished case-control study (Silverman et al, 2017).
Of the 120 London participants from the study;

•

47.5% (n=57) said that opioids were their preferred drug, where 27.5% (n=33)
specifically stated that they preferred Hydromorph Contin as opposed to opioids in
general.

•

83.3% (n=100) disclosed having used Hydromorph Contin intravenously within the
past 3 months. There was a selection bias in the recruitment as many of the
participants were interviewed at the needle and syringe program in London.

•

82.5% (n=99) disclosed having used Crystal Methamphetamine within the past 3
months.

•

12.4% (n=15) disclosed having used heroin within the past 3 months.
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The remainder of the paper will be focusing on the chart review dataset which is explained in
the next section.

2.7 Objectives, Hypothesis, and FINER Criteria
The following include the objective and hypothesis for all sections of the analysis,
with the structure adapted from Farrugia et al (2010):

Section: Baseline Characteristics.
Research Question: Which variables are significantly different between the PWID and nonIDU subsets?
Research Hypothesis: Consistent with the literature, a significant majority of right-sided,
specifically affecting the tricuspid valve, infective endocarditis occurs among PWID, with
Streptococci species being most prevalent throughout both groups. Also, due to the stigma
associated with the use of injection drugs, number of patients receiving surgery will be
significantly higher among non-IDU patients.
Objective: Investigate how characteristics differ among patients with infective endocarditis
depending on their use of injection drugs.

Section: Incidence Estimation Analysis.
Research Question: How has the incidence of infective endocarditis changed over time
relative to the growth of the population?
Research Hypothesis: Infective endocarditis has been growing at a greater pace among
PWID than non-PWID.
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Objective: Determine the incidence of Infective Endocarditis in London, Ontario by
injection drug use status.

Section: Survival Analysis.
Research Question: How does the use of injection drugs influence survival outcomes
without accounting for other covariates (Kaplan-Meier)?
Research Hypothesis: PWID are at a lower risk of death initially, although over the
timespan of the dataset their cumulative hazard surpasses non-PWID in a statistically
significant way.
Objective: Assess the influence that the use of injection drugs has on the probability of
survival over time.

Section: Survival Analysis.
Research Question: Which variables are associated with an increased hazard of death
among PWID patients with infective endocarditis (Cox PH model)?
Research Hypothesis: HIV, age in years, MRSA infection, and HCV are most significantly
associated with death in the model.
Objective: Determine which variables have the greatest influence on survival in PWID after
adjusting for other clinically relevant variables.

The FINER criteria for a good research question (Farrugia et al, 2010) will be used to further
build the rationale underlying this thesis topic.
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Feasibility - There were 377 total patients included in the analysis, 204 of which were
PWID. The number of PWID patients exceeded that of all single-city studies that have been
reviewed in the introduction and literature review.

Interesting - The number of endocarditis patients in London, Ontario that use injection drugs
is an anomaly in terms of magnitude and proportion, which increases interest among
researchers of PWID. The influence of this high rate of IE leads to interesting questions
regarding the incidence of IE relative to common estimates found in the literature. This rich
dataset also allows for a thorough examination of PWID with IE and the unique risk factors
that influence this subset of the population.

Novel - Considering there is no dataset found in the literature that contains the proportion of
PWID with IE that are found in London, the results of this study are certain to be novel.

Ethical - All data was collected with the approval of an ethics committee.

Relevant - With the rise of prescription opioid injection drug use in North America,
understanding the associated risks is relevant. These findings have the potential to influence
funding for addiction treatment and harm reduction services, as well as future research into
other health outcomes associated with the use of injection drugs.
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Chapter 3

3

Data and Methods
This analysis used data from a medical chart review of all patients in London, Ontario

that have been admitted with definite infective endocarditis. Missingness was found
throughout the dataset. When possible, values were inputted using a clinical rationale. The
analysis was conducted using R and it’s many useful statistical packages. The methods
include an assessment of baseline characteristics, an incidence analysis, a univariate survival
analysis (Kaplan-Meier), and a Cox Proportional Hazards multivariable analysis.

3.1 Data
This dataset included all first-episode patients from February 28, 2007 to March 15,
2016 with a discharge diagnosis of Infective Endocarditis. Patients with ages greater than 65
years old upon admission were included at a later date and as such, their censoring dates
were as recent as July of 2017. All cases were reviewed by resident physicians Dr. Adeel
Sherazi and Dr. Esfandiar Shojaei to assure that they fulfilled the modified Duke criteria for
definite IE. The resultant dataset included 371 first episode patients over the 9-year
timespan, all of which have confirmed definite IE. The start time in this dataset occurs upon
the clinical diagnosis of infective endocarditis and as such this is a historical cohort (Szklo,
pg. 23). There was little opportunity for informative censoring because in Ontario, deaths
must be confirmed by a medical professional and would therefore be available on a chart
review for a patient (handbook on medical certification of death, 2010). The type of
censoring that occured with this dataset would be considered “administrative censoring” as
some patients had not yet died by the end of the data collection period (Moore, pg. 3).
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The possibility of informative censoring may exist among PWID that did not seek
medical treatment for IE. Any death that occurred because of inadequate treatment would
possibly fail to be attributed to infective endocarditis. Overdose or sepsis may have been
concluded despite the true cause of death being directly related to infective endocarditis.
Some data from the introduction was taken from a separate case-control separate
study. This data was collected by myself (Brian Hallam), Laura Ball (UWO medical
student), Ryan Wong (Medical Sciences Undergraduate student), and Dr. Michael Silverman
(Infectious Disease Physician). This dataset had some unavoidable limitations such as the
recall bias with time-dependent covariates (i.e. changes in injection drug use frequency). The
selection of participants was highly susceptible to selection bias as the interviews were
conducted at a needle exchange, a hospital, or an HIV clinic. As such, the analytics found in
this paper focused exclusively on the chart review dataset.

3.2 Missingness
The problem of missingness is a serious one as it requires imputation or omission,
both of which may create bias and lead to difficulties in the analysis. Dealing with
missingness is particularly problematic when the observations are not missing at random, as
is likely the case with our dataset. For example, the HIV-positive variable contained 190
unclear responses. In this case, missingness is very unlikely to occur at random. “UNC”, or
unclear, was written for all patients who were not questioned regarding their HIV status. As
such, their information is unavailable and would be coded as such for analysis. This is a
major issue as people who inject drugs are much more likely to be questioned for infectious
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diseases, whereas it may not be deemed necessary to ask patients who do not use injection
drugs.
In this situation it is intuitive to code the “unclear” observations as not having HIV, as
it can be assumed that the physician decided it was not relevant. Of course, if the patient had
HIV, a concurrent infectious disease would be pertinent, and therefore written down. The
same assumptions were made with unclear HCV statuses, for which there are 138 unclear
observations. This was a limitation of the study.

3.3 Methods Overview
The full analysis was conducted with a desire to ensure reproducibility. All analyses,
including clean-up, were conducted using R software (R Core Team, 2013). Beginning with
a .xlsx file format, I created a sheet titled “Thesis” that included all the variables required for
the analysis, imported that dataset into R, then cleaned and performed the analysis
transparently and in a reproducible manner while providing a rationale for any
modifications. Effort was made to create an output that was tidy based on the Hadley
Wickham definition (each column is a variable and each row is an observation) (Wickham,
2014).
The dataset included hospital chart review data of all definite cases of first-episode
infective endocarditis in London from 2007-2016. (1) baseline characteristics such as
demographic information, the frequency and proportions of right-sided versus left-sided
endocarditis, and types of bacteria will be explored, differentiating by both PWID versus
non-PWID as well as by the outcome variable of interest, Death. Next, an (2) incidence
calculation using annual first-episode IE relative to the population of London, Ontario. The
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population data was publicly available from Statistics Canada (Statistics Canada, 2017) and
is available for viewing in the appendix (Table 3). To assess the influence of infective
endocarditis on survival, we then performed a (3.1) survival analysis using Kaplan-Meier
survival curves to differentiate those who inject drugs with non-PWIDs, with a
corresponding log-rank test to formally assess whether differences in survival exist between
these two groups. Lastly, to determine which factors have the greatest influence on
mortality, a (3.2) Cox proportional hazards model models was calculated, with brief
rationales for each independent variable included. All models were based on first-episode
patients only, and injection drug use was modelled as an independent variable to assess the
influence on death, one of the major objectives of this analysis.

3.4 Baseline Characteristics
Baseline characteristics include values for the entire sample, PWID-only, and nonIDU-only subgroups using frequencies and proportions with binary indicators and median
and standard deviation for age, the only continuous variable. The design of the baseline
characteristics table found below is largely influenced by the baseline table found in an
endocarditis study by Shrestha et al (2015). The probability values were calculated using
tests of two independent proportions (chi-square tests of independence) where appropriate
(BU, 2016). In situations where counts were less than five, Fisher’s exact test were used
(D’Agostino, pg. 375). Independent and dependent baseline characteristic variables of
interest as well as a brief rationale regarding significance are provided in table 4 from the
appendix.
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3.5 IE Incidence in London, Ontario
Incidence analyses are used for categorical dichotomous outcomes (Szklo, pg. 47),
and in our case that outcome was a confirmed diagnosis (“definite case”) of infective
endocarditis. Incidence takes the form:

𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 =

𝐴𝑛𝑛𝑢𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑒𝑤 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑒𝑠
100 000 𝑝𝑒𝑟𝑠𝑜𝑛 𝑦𝑒𝑎𝑟𝑠

The annual number of new diagnoses were gathered using the chart review (firstepisode only) and creating subsets for each year. The denominator, population size of
London, is publicly available from Statistics Canada. Table 3 from the appendix shows
column headings that include variables for Year, Annual Incidence, Population Size, and
Incidence Rate. This data will then be illustrated in a bar plot (appendix: Figure 3), in a
dodged position (side-by-side) to differentiate PWID with non-PWIDs and overlaid with a
line containing a slope that was determined in a linear model of year on population.
Predicted incidence and plotting was conducted manually using ggplot2 (Wickham,
2009) as well as the Incidence package in R (Jombart et al, 2017). This package is used to
compute, visualize, and model incidence of dated events (Jombart et al, 2017) which makes it
useful for analyzing the endocarditis dataset. First, we manually plot the annual incidence,
differentiating PWID and non-PWIDs, like the plot mentioned above. Next, we modelled the
incidence using a log-linear regression which takes the form:
log(𝑦) = 𝑟𝑡 + 𝑏
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Where r is the growth rate, t is time, and b is the intercept. Recall that an increasing
logarithmic function indicates that the outcome variable, y, is increasing at an increasing
rate. This can be demonstrated algebraically:
𝑦 = 𝑒 (𝑟𝑡+𝑏)
The outcome variable, incidence of infective endocarditis, would increase
exponentially for all positive values of r, assuming 𝑏 ≥ 0, which makes sense given that you
cannot have less than zero cases. The outcome of the fitted model, both the parameter
estimates and the confidence interval, would shed light on the existence of an increasing,
decreasing, or linear trend. The accompanying visualization plots the fitted values from the
log-linear regression on a linear scale.

3.6 Time-to-Event Modelling: Survival Analysis
Simply put, “Survival analysis is the study of survival times and the factors that
influence them” (Moore, pg. 1). Time-to-event modelling is effective in its ability to deal
with observations that are terminated before the event (death) occurs. This is referred to as
censored data, which is not a major issue when the majority of observations experience an
“event” within the data collection period. In our case, censoring occurs among 249 of 371
observations, as these patients survive beyond January 1, 2016. Their death may have been
two days after, or 50 years after, and as such we must use statistical methods that adequately
account for this problem.
With binary outcomes and confounding covariates, logistic regression models are
most commonly used to make inferences about the data. The coefficients for dichotomous
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covariates are interpreted as the change in odds of death given the presence of a particular
covariate, holding all other independent variables constant. The problem with logistic
modelling in this circumstance is that they do not account for different lengths of follow-up
(D’Agostino et al, pg. 586). Alternatively stated, logistic regressions are ineffective at
dealing with censored data and ignore survival times (Kleinbaum et al, pg.98). A survival
analysis on the other hand can make use of all available time-to-event data to compare
groups with respect to time to an event (D’Agostino et al, pg. 586).
Groups with incomplete follow-up, loss to follow-up, or censoring in cohorts are
traditionally comprised of individuals who drop out for reasons unrelated to the study, such
as becoming disinterested and withdrawing their consent to participate, moving to another
district, not answering calls to collect information, etc. With the chart review dataset, we
assumed that the patients remained in the London-Middlesex region and were included for
the entirety of the data collection period. This is because all participants would have their
information collected by physicians in the region and would therefore be accessible by the
researchers that gathered the data. It is possible that participants left London-Middlesex and
subsequently died within the study period, and this was a limitation of the study.
Censoring with survival data must be non-informative. This would mean that any
individual that is censored at the end of the follow-up period should be representative of all
other subjects with the same values for explanatory variables that are also censored (Cox et
al, 1984). In the regression modelling, this assumption is met through the inclusion of
pertinent independent variables that would likely affect the rate of censoring, such as age,
vegetation location, intravenous drug use, primary bacteremia, etc.
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3.6.1

The Kaplan-Meier Method

The survival analysis was conducted using the Survival package in R (Therneau,
2015) (Therneau and Grambsch, 2000). The analysis begins with the Kaplan-Meier method
which takes the form:
𝑓−1

̂ (𝑇 > 𝑡(𝑖) |𝑇 ≥ 𝑡(𝑖) )
𝑆̂(𝑡(𝑓−1 ) = ∏ 𝑃𝑟
𝑖=1

This provides estimates for the survival function, S, which is a product of the
probabilities, Pr, of individuals within a chosen group surviving past the previous failure
time, 𝑡(𝑓−1) , given that they were alive at time t (Kleinbaum et al, pg. 66). T represents time
in days since the admission until an “event”, or in our case, death. A simpler description is
provided by Goel et al (2010), as they described the product limit estimate as a product of
survival over time intervals, where each is calculated by taking the number of subjects living
at the start less the number of subjects that died during that period, all over the number living
at the start (Goel et al, 2010). The shorter these time intervals are, the more accuracy is
contained in the calculation. With the chart review dataset, we were fortunate to have time of
death right down to the second, although the variables were reformatted from date and time
(POSIXct) to date-only for the analysis.
The survival outcome was then transformed into an illustration, the Kaplan-Meier
curve, which is a monotonic (never increasing in this case) step function (Kleinbaum et al,
pg.53). The Kaplan-Meier method creates a new interval each time there is an event,
utilizing conditional probabilities to plot survival over time. The Kaplan-Meier method,
however, is unable to account for covariates without running separate subgroup
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analyses. This is a limitation of the method, although the upside to using the Kaplan-Meier
method is that it provides easily interpretable outcomes. A more thorough analysis was
completed using Cox proportional hazard regression models later in this section.
In our plot, each survival function used grouped data based on one variable of interest
to generate each respective survival curve. The first effect parameters in the Kaplan-Meier
analysis are PWID vs. non-PWID. We will use our data to answer how the probability of
survival using all-cause mortality varies over time, differentiating by injection drug use
status. This is followed by a log-rank test that tests the hypothesis that there is no difference
between groups. The corresponding p-values determine the probability of differences being
at least as large as is calculated using the method, given the null hypothesis is true, or that the
two groups are truly the same. Alpha values below 0.05 will be considered statistically
significant. Kaplan-Meier analyses was also performed using first-episode PWID only,
investigating the survival curves associated with:
1. HCV positive vs. negative
2. HIV positive vs. negative
3. Homeless vs. Housed
In these circumstances, the PWID-only dataset must be used as there are insufficient
events for non-IDUs.
The log-rank test was chosen instead of the Wilcoxon statistic or other options due to
its sensitivity to test differences in groups at later points in time (Allison, pg.42). The
Wilcoxon statistic is the weighted sum of deviations between observed and expected effects,
whereas the log-rank test is the sum of deviations between observed and expected. As such,
more weight is given to the events that occur earlier in the study period with the Wilcoxon
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statistic. In the literature review it was shown that in-hospital, or short-term, mortality rates
do not have statistically significant differences between PWID and non-PWIDs (Wallace et
al, 2002) (Chu et al, 2004). The significant separations occur more than 6 months after
diagnosis (Wallace et al, 2002). Being sensitive to the differences when they are most likely
to occur is therefore necessary for this type of analysis.

3.6.2

Cox Proportional Hazard Model
A more rigorous analysis is conducted using a Cox Proportional Hazard model which

determines the instantaneous risk of the outcome, death, compared with a baseline as a
multiple of the underlying hazard (Szklo, pg. 266). The coefficients from a Cox PH model
are the log hazard ratios, which is a multiplicative measure of association (Szklo, pg. 267).
For example, the interpretation of a coefficient would be, “a one-unit increase in 𝑥1
corresponds to a 𝑒 𝛽1 times increase in the outcome variable, adjusted for other variables in
the model.”
As mentioned previously, logistic regressions are not suitable for this type of analysis
because they do not account for censoring or survival times. Although the Cox model is
more accommodating for time-to-event data, it is a semiparametric model with no
interpretable intercept, only a baseline hazard. If the covariates are centered (replace X with
X-E[X]), only the baseline hazard changes and the coefficients remain the same (Klein, pg.
9). This means that our inferences are only relative to the reference for any particular
covariate holding all others equal. This is the type of modelling is used in health and medical
sciences because of its flexibility (Moore, pg. 25). The Cox proportional hazards model uses
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partial likelihood to loosen the assumptions via an unspecified baseline survival distribution
(Moore, pg. 56). For example, the coefficient corresponding to PWID, call it β, represents an
𝑒 𝛽 hazard ratio, or an 𝑒 𝛽 increased hazard of the outcome relative to non-PWIDs, holding all
other independent variables equal. As with the Kaplan-Meier method, the Cox model can
describe the hazard of the outcome for a subject with specific covariate values given that they
are still alive at time 𝑡 (Vach, pg. 88). The ability to extend this model with many different
covariates is what makes the Cox model particularly useful.
Whereas linear models assume a linear relationship between outcome variable and
predictors, logistic regressions do the same on a logit scale (Stoltzfus, 2011), the Cox
proportional hazards model assumes a constant proportional relationship. This would mean
that holding all else equal, any given predictor corresponds to a constant 𝑒 𝛽 times increase in
the hazard of death over the life course. Alternatively stated, the variables in the model are
time-independent (Kleinbaum et al, pg.95). With the chart review data, the timeindependence assumption is suboptimal although not a major flaw as the data collection
period is less than a decade.
In the presence of ties, for which there are 21 durations repeated twice and one
duration repeated three times, the Efron method was used. This method was chosen as it has
been shown in estimation studies to be preferable over the Breslow method (Hertz-Picciatto
and Rockhill, 1997).

3.6.2.1

Predictor Selection Procedure for Full Model

The goal of the model is to determine the minimally confounded estimate of injection
drug use on survival (Vittinghoff, pg. 222). To minimize the risks of over-fitting, variable
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specification was based on all clinically relevant data that had been motivated in the
introduction and literature review (Vittinghoff, pg. 401). Attention was also paid to
temporality to prevent the inclusion of mediating variables in the model. A simple example
of this would be found in a model that includes both bone/joint infection (Y/N) and Septic
Shock as independent variables. In this example, the bone/joint infection would mediate the
sepsis and therefore provide biased estimates for both as they pertain to death, downward in
the case of bone/joint infection and upward in the case of sepsis.

Bone infection → Sepsis → Death

A mediation analysis is not conducted as it was not considered in the original
hypothesis, although a clinical rationale will be applied to prevent mediating variables from
being included in the model.
In concordance with events per variable minimum of ten events per variable (EPV)
(Peduzzi et al, 1995), all pertinent variables that were discussed in the introduction/literature
review and do not mediate the effect of more proximal variables were included in the
model. The results of this analysis suggest the influence of injection drug use on survival
outcomes, which is one of the main objectives of this paper.
There are cases when variables were omitted despite the presence of more than ten
events. This was done to avoid confounding variables. A strong example of a variable that
was omitted to prevent confounding was with the variable Negative, indicating tests for
bacteria in the blood returned negative. To be a Duke “definite” case of endocarditis, which
all the patients included in the dataset were confirmed to be, required either two major
criteria, one major and three minor, or five minor criteria (refer to table 2 from the
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appendix). Given that a positive blood culture cannot be one of the criteria (hence, negative)
and the number of people that had vegetations present was 367 (97.1%) and there is not a
reliable way to determine the severity of the vegetations, the negative would have indicated
between three and five minor criteria present. One of these minor criteria would be the use of
injection drugs, which presents a clear multicollinearity problem. The takeaway is that the
use of negative in the model would be guaranteed to carry multicollinearity problems due to
conditions of the inclusion criteria for the dataset.
The variables in the model included:

1. Age - continuous variable representing age in terms of years
2. Female - representing the female sex relative to males
3. Fever - patients presenting fever upon admission
4. PWID - people who inject drugs
5. Microorganism - MSSA, MRSA, Enterococci
6. Valve Affected - Aortic, Mitral, Tricuspid, Multi-valve
Limited Right-sided infective endocarditis was not included in the model despite meeting
the minimum event threshold. This is because of the interaction that would exist between the
variables limited right-side and tricuspid, as most of the patients affected with tricuspid valve
IE would also be limited to the right side. The variables Skin and Soft Tissue Infection,
Bone/Joint Infection, Respiratory Infection, Septic Shock, Renal Failure, and Surgery were
not included in the model due to the temporality bias that would introduce. As mentioned
previously, these variables are often not presented upon admission. Many of the variables
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mediate death, and as the most proximal variable to the outcome, they would dominate the
variables that we are interested in determining the significance of.

3.6.2.2

Predictor Selection for Secondary (PWID-only and non-IDUonly) Models

Like the Kaplan-Meier analysis, a separate Cox proportional hazards analysis was
performed using a PWID-only subset of data. This included clinically relevant variables that
were omitted in the previous model due to an unsatisfactory number of events per variable
among non-IDUs. These variables have all been written in italics and underlined. The
variables in the PWID-only model include:

1. Age - continuous variable representing age in terms of years
2. Female - representing the biological sex relative to males
3. Fever - patients presenting fever upon admission
4. Homeless – no registered address or identified as homeless
5. Microorganism - MSSA, MRSA, Enterococci, Polymicrobial
6. Valve Affected - Aortic, Mitral, Tricuspid, Multi-valve
7. HCV + - Positive for Hepatitis C Virus
8. HIV+ - Positive for HIV

The variable indicating Both Right- and Left-sided Vegetations is not included in the
model as its effects are captured within the variable Multi-valve.
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The same process and rationale will be used in the third and final model, using the
non-IDU patients only. Again, modifications from the total model will be italicized and
underlined.

1. Age - continuous variable representing age in terms of years
2. Female - representing the female sex relative to males
3. Fever - patients presenting fever upon admission
4. Microorganism - MSSA, MRSA, Enterococci, Alpha-Hemolytic Streptococci,
Coagulase Negative Staphylococci
5. Valve Affected - Aortic, Mitral, Tricuspid, Multi-valve, Prosthetic Valve
6.

Intracardiac Device and/or Pacemaker
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Chapter 4

4

Results

The results are broken down into baseline characteristics, incidence analysis, and survival
analyses. This section is devoted to stating the results and interpretation of the analysis.
Impact and significance will be explored further in the discussion section.
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4.1 Description of the Sample

Table 6: Results for baseline characteristics, differentiated by total group, PWID and
non-IDU.
This sample contained 377 patients with first-episode of Infective Endocarditis, 204
(54%) of which used injection drugs based on the chart review. The baseline characteristics
by injection drug use (found in table 5) illustrated many significant differences between
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PWID and those who do not use injection drugs. The age upon admission for PWID with
first-episode endocarditis showed PWID to be younger by 24.4 years (95% C.I. 21.7 to 27.0,
p < 0.001). This difference was also clinically significant and suggests that any inferences
derived from the Kaplan-Meier curve should not be considered too deeply, as these two
populations are very different in terms of a variable that has a very strong relationship with
the probability of death: Age. The majority of PWID with IE are male, although the ratio of
male:female is much lower for PWID than non-IDU with IE. This suggests that all else
being equal, men appear to be more likely to be diagnosed with infective endocarditis in
general, although among PWID the difference in proportional diagnosis between men and
women is not significant in this sample. Homelessness, on the other hand, is a variable that
is found solely among PWID. Of the 35 patients in this sample that had no known address,
all were PWID. The proportion of the sample that died was not significantly different
between the two groups, nor was the proportion that had positive blood cultures. Since there
were 11 levels for the categorical variable microorganism, only a chi-square test of
association was performed to prevent the risk of spurious relationships. Notable differences
occurred with MSSA (57.8% of PWID and 23.1% non-IDU), MRSA (22.6% of PWID and
9.47% non-IDU), and Alpha-Hemolytic Streptococci groups (4.02% of PWID and 32.5%
non-IDU). The categorical variable indicating which valve the vegetation occurred on was
similarly only tested using a measure of association, which showed very significant (p-value
< 0.001) differences between PWID and non-IDUs. The non-IDUs had both relative and
absolute greater levels of Aortic (41.5% vs. 14.4%) and Mitral (35.1 vs. 11.8%) vegetations,
both of which occur on the left side of the heart, whereas PWID had the majority of
Tricuspid vegetations (7.02% vs. 62.1%). PWID also had significantly higher frequencies of
HIV, HCV, skin and soft tissue infections, respiratory infections and septic shock. Non-IDU
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had higher frequencies of intracardiac devices, prosthetic valves, renal failure, and surgery
for IE.

4.2 IE Incidence in London, Ontario

The data suggests there is an increasing annual incidence of infective endocarditis
within all groups (total, PWID, and non-IDU). The total model was able to estimate the
incidence rate as a function of the population of London, Ontario. Since we did not have
estimates regarding the size of the underlying PWID population, we were only able to
provide estimates based off the annual count. The cases of IE are rising faster among PWID,
with a linear regression (predicting number of PWID cases over time) showing a coefficient
value of 3.33 (95% CI 1.47 to 5.20) for PWID compared to 2.87 (95% CI 1.79 to 3.94) for
non-IDUs, which indicates that with each year, there is an increase in IE of 3.33 and 2.87
cases, respectively. These confidence intervals intersect, indicating that there is not a
statistically significant difference in annual incidence between PWID and non-IDUs. The
year 2016 was omitted from the plot as the year was not complete at the end of the data
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collection period and created a downward bias in the regression lines. There was a relatively
low incidence in 2012 for both PWID and non-IDUs, although the counts returned to trend
the following year for both groups.

When broken down into 3-month
intervals as shown in the adjacent
figure, the log-incidence model
exploring the growth rate that
influences the incidence of
Endocarditis yielded a parameter
estimate of 1.16 (95% C.I. 1.10 to
1.21). This positive, statistically
significant estimate indicates that the rate of infective endocarditis is increasing, and at an
increasing rate. When differentiating log-incidence by IDU status, we find that the growth
rate is only significant for non-IDU patients (1.14, 95% C.I. 1.07 to 1.21), although the
absolute value of the coefficient is higher for PWID (1.15, 95% C.I. -1.02 to 1.34). The
magnitude of increase is larger (albeit statistically insignificantly) for PWID in comparison to
persons who do not use injection drugs. Although the data may be suggestive of a larger
magnitude of growth among PWID, the results do not have sufficient significance to draw
conclusions. We are unable to conclude that there is a significantly widening gap in the rate
of infective endocarditis based on the results of this analysis.

4.3 Survival Analysis
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This analysis includes a univariate Kaplan-Meier analysis of IDU status on death, as
well as HCV status, HIV status, and homelessness. Next, a Cox proportional hazards model
explores the variables associated with death, controlling for other variables in the model.

4.3.1

Kaplan-Meier Method and Log-Rank Test

The Kaplan-Meier method demonstrated that participants in the sample experienced a
sharp decrease in survival probability upon admission, which gradually tapered off. Within
30 days, the survival probability for both groups combined was 85.3% (95% C.I. 81.8% to
89%) which is consistent with the literature’s 16-19% in-hospital mortality rate.
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Regarding 30-day survival, the results were similar to the total for both non-IDU
(0.853, 95% C.I. 0.801 to 0.908) and PWID (0.848, 95% C.I. 0.800 to 0.899). During the
entire course of follow-up, the survival probability reached lows of 0.572 for non-IDU in 8.7
years (95% C.I 0.429 to 0.764) and 0.576 for PWID in 7.4 years (95% C.I. 0.480 to
0.692). The Log-Rank test for differences in survival distributions yielded a probability
value of 0.641, indicating that there were not statistical differences between groups (non-IDU
vs. PWID). This p-value states that distribution differences as large or larger can be found
within the same sample nearly 65% of the time, which is much greater than the traditional
cutoff of 5%. The summary statistics showing survival functions for each time interval can
be found in the appendix (Output 1).
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This represents the same illustration as shown above it, less the survival curve for
non-IDUs. Below, the figures indicate that there are many more variables that influence
survival beyond the use of intravenous drugs. Summary statistics can be found in the
appendix (Output 2).
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A majority of the PWID subset had Hepatitis-C Virus, although based off this
univariate analysis it appeared to be protective, and significantly so as the log-rank test
statistic contained a probability value of 0.045. Likely due to the inadequate power that
results from relatively few number of patients with HIV, the difference in survival outcomes
between HIV-positive and HIV-negative patients was not statistically significant. Lastly,
using a univariate analysis, being housed did not appear to have independently predictive
value regarding survival.
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4.3.2

Cox Proportional Hazard Models

4.3.2.1.1

Full Model

The full model contained all patients without omitted data, which resulted in an
analysis of 353 patients with infective endocarditis. MRSA was found to be the most
significant variable in the model, suggesting that the presence of MRSA is most strongly
associated with an increased hazard of death after controlling for other variables. Patients
with Methicillin-Resistant Staphylococcus Aureus infections were found to have a 3.23 (95%
C.I. 1.79 to 5.84) times greater hazard of death after controlling for other variables than
patients without an MRSA infection. In order of statistical significance, the next variable
was age. A one-year increase in age corresponded to a 1.03 (95% C.I. 1.01 to 1.05) increase
in hazard of death after controlling for other variables in the model. Intravenous drug use,
one of the major objectives of the hypothesis, was found to be associated with a 2.50 (95%
C.I. 1.41 to 4.34) times increase in hazard of death after controlling for the other variables in
the model. Lastly, MSSA was also shown to be associated with death (1.74, 95% C.I. 1.05 to
2.87). Summary statistics may be found in the appendix (Output 3).

4.3.2.1.2

PWID and non-IDU-only Models

The following models were generated using PWID-only data and non-IDU-only data,
respectively, and therefore produced results that are not necessarily aligned with those found
in the full dataset. All interpretations may be preceded by, “After controlling for intravenous
drug use”. This model permitted the inclusion of infectious diseases (HIV and HCV), which
were both found to be statistically significantly associated with the hazard of death. A
patient with an HIV-positive status had a 3.62 (95% C.I. 1.45 to 9.04) times greater hazard of
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death relative to patients that were HIV-negative after controlling for other variables. An
HCV-positive patient, as demonstrated in the Kaplan-Meier curves, are at a lower hazard of
death in our models (0.52, 95% C.I. 0.30 to 0.93). Summary statistics for PWID-only and
non-IDU-only models may be found in the appendix (Output 4 and Output 5, respectively).
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Chapter 5

5

Discussion
This chapter discusses the research findings in the context of the literature provided in

the earlier chapters. Key findings pertaining to each objective will be interpreted and their
potential implications discussed. Strengths and limitations of this research will then be
explored, with an emphasis on the omitted variables bias that exists within this work. Lastly,
a discussion on the generalizability of the findings and directions for future research.

5.1 Baseline Characteristics
The baseline characteristics of this sample were unique in both their frequency and
proportion of injection drug users. The number of patients with infective endocarditis who
used injection drugs totaled 204, or 54% of the sample. Comparably, Wurcel et al (2016)
commented on the rising IDU-associated IE in the United States as they have reached a high
of 12.1% in 2013, substantially less than that which is found in London, Ontario. The more
recent analysis by Tung et al (2015) in British Columbia found the proportion of IDUassociated IE in their samples to rise from 5% in their first cohort (2002-2006) to 15% in
their second (2009-2013), which is less than a third of what was found in London. The high
proportion of IDU-associated IE has significant implications regarding risks of mortality and
costs associated with high recurrence rates. These peculiarities can result in misleading
admission data, as the number of people being treated will increasingly often have had
endocarditis at a previous time. Beyond placing an excessive financial strain on the hospital,
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each admission following the first-episode would place the patient at a higher risk of death.
This is the rationale for using only first-episode data in the analysis.
Beginning with the main outcome of all the models, all-cause mortality, the tests of
proportions and log-rank test indicate that there was no significant difference between patient
groups. Recall, research conducted by the World Health Organization suggested that the
standardized mortality ratio for PWID in North America was 11.19 (95% C.I. 3.58 to 18.80).
Our dataset includes only patients with infective endocarditis, and therefore only accounts for
those that die from/with IE and not a true representation of all-cause mortality. With that
being said, for this SMR calculation to be accurate in London, Ontario, it would require
approximately 4.98% of the population to use injection drugs (calculations can be found
within the appendix: Equation 1). This number is unlikely to be accurate due the WHO SMR
being derived from the population, not those with a disease that is particularly prevalent
among PWID. This percentage is therefore unreasonable and likely to be quite inflated. It is,
however, reasonable to suggest that the risk of death associated with infective endocarditis
for PWID relative to non-IDUs is much higher than the SMR of 11.19 that was calculated by
the WHO.
With regards to differences in proportions between PWID and those who do not use
injection drugs, staphylococci and streptococci species were most common in all subgroups
within the sample, with MSSA representing 41.8% of the patients and MRSA 16.6%. This is
consistent with the findings in the North American literature. Staphylococci species have
adherence properties that increase their likelihood of forming a bacterial vegetation on the
heart valve. Regarding PWID, 80.4% of patients in the sample had MSSA (n = 115, 57.8%)
or MRSA (n = 45, 22.6%), which meets the estimations found within the literature for
streptococci and staphylococci combined. When you add alpha- (n = 8, 4.02%) and beta50

hemolytic streptococci (n = 3, 1.51%), that proportion rises to 85.93%. For non-IDU
patients, staphylococci and streptococci species also make up a strong majority of the
primary organisms (n = 133, 78.73%), although the distribution is quite different. Among
staphylococci species, MSSA (n = 39, 23.1%) and MRSA (n = 16, 9.47%) were joined by
Coagulase Negative Staphylococci (n = 18, 10.7%), which had zero cases amongst PWID.
The most common bacteremia for non-IDU patients were alpha-hemolytic streptococci
species, representing 55 (32.5%) of the cases amongst non-IDU patients. The tendency
towards MSSA and MRSA among PWID may be attributed to the unique adherence
properties of staphylococci species (Frontera et al, 2000). The adherence properties are
usually discussed in the context of prosthetic valves, although among PWID the adherence
may occur to the particulate matter which is then injected intravenously. Repeated washes
provide a useful explanation for how this may occur. As suggested by Roy et al (2011),
users often require multiple injections in one sitting and leftover residue is often saved for
later or sold. This provides an exposure whereby bacteria such as staphylococcus aureus can
latch on and receive a free ride to the tricuspid valve.
The tricuspid valve was most common among PWID, appearing in 62.1% of cases
compared to 7.02% among non-IDU (p-value; < 0.001). The cox models also demonstrated
that among both the total and PWID-only subset, right-sided (tricuspid) IE was associated
with a more favourable prognosis, as was suggested in the introduction by Cahill et al
(2016). This may be a rationale for why PWID are much less likely to receive surgery for
their endocarditis. Regarding surgery for IE, 99 (57.2%) of non-IDU patients received
surgery, compared to 39 (19.1%) of PWID resulting in highly significant differences between
the two groups (p-value; < 0.001). While this information alone is inadequate to reliably
infer the explanation for this phenomenon, an implication would be that those who use
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injection drugs as they are less likely to be viable candidates for surgery. Guidelines by the
American College of Cardiology state that indications for surgery for native valve
endocarditis are a function of the severity of the condition, such as the presence of valve
stenosis regurgitation, elevated left ventricular end-diastolic or left atrial pressure, and those
caused by highly resistant organisms (O’Gara, 2007). Highly resistant organisms, such as
MRSA, appear to be much more common among PWID, although it is possible that they
present with less severe vascular damage, on average. Alternatively, it is possible that some
surgeons are averse to operating on patients that are likely to continue the adverse lifestyles
that are associated with premature infectious diseases, injection drug use in this instance.
Analogous to the alcoholic that is ineligible for a liver transplant, PWID may not be priorities
due to their risk of recurrence and the finite supply of cardiac surgeons.
There were many significant differences found between characteristics of PWID vs.
non-IDU that have not yet been discussed, similar to that which is most commonly found in
the literature. Furthermore, some pertinent characteristics such as HIV-positive status, HCVpositive status, prosthetic valves, homelessness and many of the microorganisms could not be
accurately compared between the two subgroups due to a lack of events in one of the
groups. Among the PWID-only subgroup, the proportion of those with HIV were 7.88%,
compared to 5.5% found within the I-track London sample and 11% found in the national
sample. Regarding HCV-positive patients, the PWID-only subset contained 70.4%
compared to 79.1% with I-track London and 68% across the country. The proportions of
PWID with these infectious diseases seem to be consistent, with our data lying between the
local and national I-track numbers.
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5.2 Incidence Estimation
The results of our incidence analysis failed to reject the null hypothesis, which was
that the incidence of infective endocarditis was increasing at a faster rate among PWID in
comparison to non-IDUs. This should be interpreted cautiously as the size of the base
population for PWID is unknown and may have changed over this timespan. The results
were statistically insignificant, although as a group the log-incidence was positive and
significant. The implication of this finding is that the number of cases of first-episode
infective endocarditis can be expected to not only increase, but increase at an increasing rate
over time. The public health implications in terms of person-years will become increasingly
substantial over time, and the costs associated with the treatment of this condition will
become increasingly burdensome. With constraints on healthcare funding and medical
expertise, London will continue to face great difficulties in overcoming the physical and
financial toll of infective endocarditis among both PWID and non-IDUs.
Much larger studies have shown that the incidence of Infective Endocarditis to be
between 2.4 to 11.6 cases per 100,000 person-years. Using London data, the incidence was
on the lower end at the beginning of the collection period (3.97, 3.74 for 2007 and 2008,
respectively), then gradually increased to reach 11.85 cases per 100,000 person-years in
2013, and a high of 12.25 in 2015. There was a substantial drop in 2012 (9.60 in 2011 to
5.87 in 2012) which promptly returned to trend in 2013 (11.84 per 100,000 person-years).
This is largely driven by PWID, as they represent most of the patients in the data set. As
discussed previously, estimates of the source population would be required to provide
incidence data as it pertains to the PWID subgroup, and this is unavailable. In any case, the
incidence in London, Ontario is above that which has been found in reviews by Klein et al
53

(2016) and Cahill et al (2016) suggesting a serious public health crisis. It is also worth
reinforcing the fact that this is only using first-episode IE patients. This does not account for
the readmissions that are common among PWID, and PWID are disproportionately
represented with an unprecedented majority in this patient sample. Quantifying the health
implications and costs associated with infective endocarditis in London, Ontario is a
direction for future research, particularly considering the constraints on hospitals and
healthcare services.

5.3 Survival Analysis
5.3.1

Kaplan-Meier Method
In the combined sample, 30-day mortality (14.7%) was similar to that found

throughout the literature (16-19%). The first date that has a recorded death after 90 days was
at the 107-day mark, which corresponds to a survival probability of 81.9% (95% C.I. 0.781 to
0.859), or a mortality probability of 18.1% (95% C.I. 0.14 to 0.22). This is compared to 6month estimates of 27% (Wallace et al, 2002) and 22% (Hill et al, 2007). This indicates a
more favourable prognosis in our sample, particularly so if the patient survives past the first
30-days.
The use of injection drugs alone was not associated with a decreased probability of
survival in a univariate, Kaplan-Meier survival analysis. This lack of statistical significance
has large implications as the population characteristics differ so substantially with regards to
age, microorganisms, and valves affected. The PWID subsample mean age was nearly 25
years younger than their non-IDU comparators (35.5 vs. 59.9). Also, the literature suggests
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that PWID typically have a more benign first episode of IE (Palepu et al, 2002), which is not
the case here. Given the universally recognized significance of aging and the increasing
prevalence of IE among younger adults, this lack of significance is alarming.
The additional analyses provided some unexpected findings. We found significant
differences in survival outcomes for those with HCV, although they have favorable
outcomes. This is counterintuitive as it is generally safe to assume that a viral infection does
not increase your odds of survival, although this has been found in the literature
previously. In examining the differences in outcomes between patients with and within
chronic hepatic diseases, Seminari et al (2016) found intravenous drug use to be a protective
factor that reduced risk of death (Seminari et al, 2016). This is after controlling for age,
diabetes, chronic hepatic disease, cancer, staphylococcus aureus infection, and prosthetic
valve IE. Patients whom did not use injection drugs were found to be at an increased risk
from bacteremia for reasons that were not specified or speculated upon.
HIV-positive status was found nearly exclusively amongst the PWID
subgroup. Within the PWID sample, there was a strong trend towards HIV-positive status
being associated with a lower probability of survival, although statistical significance was not
reached. This may be due to the study duration, an inadequate sample size, or due to the high
rate of mortality among the total sample, regardless of infective disease and drug use status.
Homelessness was not associated with a difference in survival compared to
individuals that were housed. This metric was flawed in that the definition of homeless is not
specific and varies depending on the lifestyle of the patient. For example, a patient may have
an old address on their identification, or a relative’s address, despite the fact they have not
been there in years. If asked, couch-surfing may not be considered homeless by many
people, although the most precise definition would indicate couch-surfing is indicative of a
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lack of home ownership or stability, thereby making one homeless. The reality of the
situation is that the patient would have been asked, “are you homeless?” or they would have
been considered homeless if there was no known address. But even given this information,
those meeting the definition of homeless would be within a particularly high-risk subset of
those that do not own/rent property, which makes the lack of significance surprising.
The original hypothesis, PWID are at a lower risk of death initially (30-day), then
surpass non-IDUs over time (>90-day), was shown to not be true. A univariate analysis on
the use of injection drugs as a predictor of mortality showed that survival outcomes are not
statistically different between PWID and non-IDUs. This is not to say that injection drugs do
not play a role in survival outcomes, as was explored in the next section.

5.3.2

Cox Proportional Hazards Model

5.3.2.1

Full Model

The initial model, Total Group, was used to assess if the use of intravenous drugs had
any predictive value regarding survival outcomes. As expected, the use of IV drugs within
this sample showed a 2.50 (95% C.I. 1.44 to 4.34, p-value = 0.001) times greater hazard of
death than not using IV drugs, adjusted for all variables in the model. Given the risks
associated with the use of injection drugs that have been explained previously, this is
outcome is unsurprising. The analysis was necessary to warrant the IDU model.
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1. Age - This is an unsurprising finding as the aging process corresponds to an increased
hazard of death throughout the literature at large, with endocarditis patients being no
exception. The results may seem trivial (1.03, 95% C.I. 1.01 to 1.05) although the
magnitude of effect for differences in age is the hazard estimate exponentiated by the
number of years. To avoid this misleading result, it is common to present age in
terms of decades as was shown with studies in the introduction (Murdoch et al,
2009). To utilize all available information, one-year intervals were maintained in the
analysis. Recall, the sample contained an age difference of 24.4 years (95% C.I. 21.7
to 27.0, p < 0.001) between PWID and non-IDUs. This would result in a hazard of:
1.029824.4=2.05, which indicates that non-IDUs are, on average, at a 2.05 times
greater risk of death due to their age, adjusted for all other variables in the
model. Despite this, the Kaplan-Meier estimator suggests that there are nonsignificant differences in survival between PWID and non-IDUs.
2. MRSA and MSSA - as mentioned in the baseline characteristics discussion,
staphylococcus aureus contains unique adherence properties that adhere to prosthetic
valves, particulate matter, and blemished cardiac valves. The significant mortality
associated with s. aureus infection is likely attributable to the organism’s
aggressiveness (Guerrero et al, 2009). Due to the epidemiological nature of s.
aureus’ association with mortality, the specific reason why this is the case is
unknown, although most likely multifactorial (Miro et al, 2005). Among PWID, the
presence of s. aureus may be a surrogate indicator of non-sterile injection
practices. The individual that never reuses equipment, brings a flame to the cooker,
and uses alcohol swabs before injection would theoretically be less likely to be
exposed to s. aureus. Methicillin resistance, the MR in MRSA, indicates that the
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bacteria is resistant to some antibiotics that are often found to be helpful with other
strains, such as MSSA. This explains the discrepancy in the association with
mortality, with MRSA being more clinically significant due to its greater magnitude.
Adjusted for other variables in the model, MRSA was associated with a 3.23 (95%
C.I. 1.79 to 5.84) times greater probability of death relative to not having MRSA
present. Alternatively, once adjusted for other variables in the model, MSSA was
associated with a 1.74 (95% C.I. 1.05 to 2.87) times greater probability of death
relative to not having MSSA present.

5.3.2.2

PWID-only and non-IDU-only Models

Recall, the research question for the Cox model was: Which variables are associated
with an increased hazard of death among PWID patients with infective endocarditis? The
answer: HCV-positive status and HIV-positive status. Surprisingly, neither age, biological
sex, housing status, affected valve, or bacteremia were able to reach significance as a risk
factor for death in this model. The only variables to pass the alpha threshold of 0.05 were
HCV-positive and HIV-positive.

1. Hepatitis C Virus - all else being equal, patients with HCV had a 0.52 (95% C.I 0.30
to 0.93, p-value = 0.026) times hazard of death as those without HCV. This indicates
that Hepatitis-C is protective. Despite the counterintuitive findings, as viral
infections are generally associated with a less favourable prognosis, this phenomenon
has been found in the literature. For example, research on infective endocarditis in
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patients with chronic hepatic diseases by Seminari et al (2016) found that PWID was
a significant protective factor in their multivariate analysis. This is not the same,
although the counterintuitive relationship between injection drug use and chronic
liver disease is similar. Another study by Perez de Isla et al (2003) found that chronic
liver disease had a significant impact on prognosis, although intravenous drug use
was not a significant variable in their cox model. What these studies have in common
is congestive heart failure (CHF) being associated with mortality. The frequency of
heart failure is low in patients with liver disease (Perez de Isla, 2003) and heart failure
is associated with mortality. The lack of heart failure in this group may have resulted
the protective signal, despite the possibility that any individual is worse off having a
chronic liver disease. There may also be a relationship between tricuspid valve
endocarditis, which corresponds to a low incidence of complications, and injection
drug use. The implications of this finding are that there are likely other relationships
that exist between the use of injection drugs, hepatitis C, and infective endocarditis.
2. HIV - Adjusted for other variables in the model, the hazard of death is 3.62 times
higher (95% C.I. 1.45 to 9.04) for HIV-positive patients relative to HIVnegative. This finding was consistent with the pre-existing literature. Based on
findings in work by Cicalini et al (2001), there may be may relationships that exist
between HIV-positive patients. They disproportionately tend to use injection drugs,
have staphylococci as the primary organism, and have the tricuspid valve as the most
common site of infection. Of the 20 patients in the sample that are HIV-positive,
80% (n = 16) used injection drugs, 60% (n = 12) had MSSA and 20% (n = 4) had
MRSA as primary bacteria, and 60% (n = 12) had a vegetation present on their
tricuspid valves. It is difficult to parse out specifically which of these variables is
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influencing the outcome with the size of our sample. What we can gather is that there
are relationships present and they are commonly found among PWID that are
diagnosed with infective endocarditis.

It is also possible that a diagnosis of HCV-positive changes the wellness and lifestyle
considerations of the patient. An individual that might be inclined to share washes or reuse
equipment may face their teachable moment upon diagnosis. The issue that presents itself is
that if this phenomenon is to be true, would it not also apply to HIV-positive patients? The
sample size for HIV is low, although being positive is significantly associated with an
increased odds of mortality.
The final model, the non-IDU-only analysis, was similar in that there were few
significant variables found to be associated with mortality. These variables included: Age,
biological sex, MSSA, and MRSA. The rationale for each has been discussed previously in
the total group analysis.
Pacemakers and prosthetic valves did not reach significance. In evaluating the
predictors of mortality among patients with prosthetic valve infective endocarditis, Elbey et
al (2013) found that age, C-reactive protein, creatinine, New York Heart Association
(NYHS) functional classification, and large vegetations were associated with mortality. The
only variable that was included in our model was age, which did reach significance. Similar
to the explanation suggested for HCV-positive patients, having surgery that implants a
prosthetic valve may provide the incentive to change a patient’s lifestyle, cause them to
optimize their health and wellness, and prevent reoccurrence of infective endocarditis.
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5.4 Limitations
The limitations of this research may be broken into two categories: bias from omitted
variables and inadequately precise data collection.

5.4.1

Omitted Variables Bias
Omitted variables bias, a term traditionally used in economics and other social

sciences, occurs when a relevant independent variable is not included within an estimation
model (McCall, 2014). This is a problem in all statistical models, as a perfect model does not
exist. This phenomenon is usually explained through a variable such as ability. In
estimating wages or earning potential, many demographic and educational variables are
predictive, although the innate ability of the individual is always unknown and therefore
unaccounted for. One may use proxy variables, such as IQ score or Parent’s income to
determine the potential for an individual, but there are flaws with both proxies and the
underlying omitted variables bias remains. In our context, there are a handful of pertinent
variables that were unable to be included in the model. These include rather abstract
personal factors such as mental wellness, childhood traumas, sense of purpose, sense of
community, quality of support networks, as well as faith and belief systems. More reliably
quantifiable examples of potentially significant omitted variables might include annual
income, net earnings, employment status, number of dependents, credit score, education, size
of residence, number of roommates, et cetera. Even these variables serve as a proxy for the
underlying influences. For example, with a variable like education, the degree to which an
individual pursues higher education may be influenced by the environment in which that
individual was raised. A child of a parent with post-graduate education is more likely to also
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pursue post-graduate education. Research by Ford and Thompson (Ford et al, 2016) went a
step further and found that children up parents are three-fold as likely to attend the same
university as their parents. This is like a child of a medical doctor being more likely to
become a medical doctor, or the child of a professional basketball player being more likely to
become a professional basketball player.
Omitted variables bias is an issue with all statistical models, although there were
some medically relevant variables that would have been desirable in a perfect world. The list
begins with the Duke Criteria, as it would be helpful to know if certain diagnostic criteria
carry relatively more or less risks and if those risks are different based on whether the patient
uses injection drugs:
1.

Major Criteria: Organism typical to Infective Endocarditis for two separate blood

cultures.
We were able to include this variable. We did not differentiate based on major/minor
microorganism, but instead for groups of microorganisms based on virality and family.
2.

Major Criteria: Evidence of vegetation.

This variable was not included in the multivariate regression analyses, although very few
patients in the sample did not have evidence of vegetation. It may not be reasonable to
suspect that a binary variable indicating vegetation present versus no vegetation present is
adequate in this analysis. Determining the size is pertinent in parsing out the effects of
microorganisms with the effects of vegetation size (Leitman et al, 2012). It has been shown
that among older patients, staphylococcal endocarditis and large vegetations is associated
with 50% risks of mortality according to research by Leitman et al (2012). Additional
research focusing on lead associated endocarditis found that s. aureus was most often
responsible for large (>1cm) vegetations (Greenspon et al, 2014). This suggests that omitting
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vegetation size may be associated with an upward bias with the magnitude of effect for s.
aureus IE, assuming that larger vegetations are more strongly associated with mortality,
which has been consistently shown throughout the literature.
3.

Major Criteria: New valvular regurgitation

Valvular regurgitation, or leaky valves, were not included in the analysis due to the amount
of missing data. Also, the onset of a new valvular regurgitation would be difficult to estimate
and therefore introduce bias into the survival analysis. It is unreasonable to perform
echocardiograms daily due to cost and invasiveness (transthoracic echocardiography), so
reliable, precise data collection is not available.
4.

Minor Criteria: Predisposing heart condition

Rheumatic heart disease is a historical leading cause of infective endocarditis and remains a
leading cause in developing countries today. It is no longer a major cause of IE in developed
countries due to advances in technology and medicine.
5.

Minor Criteria: Intravenous Drug Use

This was included in the dataset.
6.

Minor Criteria: Fever >= 38 degrees Celsius

This was included in the dataset.
7.

Minor Criteria: Vascular phenomena, major arterial emboli, septic pulmonary

infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and
Janeway’s lesions
The number of missing events, the inclusiveness, and the unknown timing of these events
were suboptimal. There were many different types of vascular phenomena, with different
risks associated with them making it heterogenous group of morbidities. The occurrence of
the events would have presumably been during the hospital stay, at least for a portion of
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them, and we do not have time stamps for their discoveries. The focus of this analysis was
with admission data.
8.

Minor Criteria: Immunologic phenomena (glomerulonephritis, Osler’s nodes, Roth’s

spots, and rheumatoid factor)
Most patients in this dataset did not have this data available and they were therefore omitted
from this analysis.
9.

Minor Criteria: positive culture not typically found with IE

All bacteremia that had a sufficient number of events within the dataset was included in the
analysis.

Beyond the diagnostic criteria for IE, other potentially influential omitted variables
that are particularly relevant to the population of interest, PWID, include:

1. Drug Type/preferences and Polydrug Use
This is an interesting topic that may influence the risks of infective endocarditis
among PWID. Some intuition regarding drug preferences may be inferred by a meta-analysis
exploring the price elasticity of illicit drugs (Gallet, 2014). In this study, it was consistently
found that both cocaine and heroin are much more elastic (sensitive to price adjustments)
than marijuana. This means that an individual is much more likely to change their drug
consumption with changes in price. In discussing the possible explanations for this
phenomenon, the authors suggested “because heroin and cocaine users are more often
polydrug users, they may perceive greater substitutability among hard drugs, thus leading
them to be more responsive to price” (Gallet, 2014). This indicates that any external factors
that increase the cost associated with drug acquisition, such as refusing a prescription or
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delisting opioids from the ODB drug formulary, may result in a transition to a more
affordable, and possibly more dangerous, alternatives. This phenomenon is demonstrated by
the infamous OxyContin fueled opioid epidemic in the United States. OxyContin, a
prescription opioid produced by Purdue Pharmaceuticals, has been widely criticized in
popular media for introducing addictive opioids to the market on an unprecedented scale, and
upon their removal many patients turn to Heroin (Berman, 2014). This situation does not
seem to be the case in London, Ontario, as preliminary data suggests there to be relatively
low consumption, possibly due to cost, quality and access of heroin, although various
prescription opioids such as Hydromorphone Contin, Dilaudid, and Morphine Sulphate are
common. There is also the issue of polydrug use in terms of alternating between Opioids and
Stimulants, more specifically Hydromorphone and Crystal Methamphetamine.
Substitutability may seem counterintuitive given the different addictive properties between
drugs, although this is not a new phenomenon.
In the 1880’s, David Musto described the use of cocaine in the United States “as a
cure for the opium, morphine, and alcohol habits” (Freud, xxviii). Sigmund Freud was also a
strong proponent of cocaine as a cure for opiate addiction. Sir William Halsted, one of the
founders of John Hopkins medical school in 1893, replaced his dependence of cocaine with a
dependence on morphine in his later years (Imber, 2011) (Freud, xxxi). Later in life, Freud
changed his beliefs on cocaine and began to understand the substitution of an opiate for
cocaine resulted more in a “double addiction” than a therapy (Freud, xxxiii), although there
have been studies that suggest he was not entirely wrong earlier in life. In a study of
naloxone-precipitated opioid withdrawal in both rats and humans, cocaine use was shown to
reduce the severity of the withdrawal (Kosten, 1990). The point worth highlighting is that
there is a historically documented short-term interchangeability between opioids and
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stimulants, despite their different effects and mechanisms. This lends an explanation for
polydrug use among PWID, particularly so after considering the costs associated with
different drugs. Peer reviewed research has not been able to provide literature on the average
costs of drugs throughout regions in Canada, although community and online sources have
suggested that in order from most to least expensive, there is: cocaine, opioids, and then
crystal methamphetamine (Reddit, 2015). There are many more drugs that are commonly
used, although these are the common cost considerations made by PWID in London, Ontario.
The takeaway here being that as drugs become restricted and harder to access, different,
possibly more harmful drugs are substituted. Knowing when an individual used which drug
as well as the date of onset for IE would have been helpful in this analysis.
2.

Frequency of Drug Use
How often one uses injection drugs influences the exposure to particulate matter

which may increase the risks of IE. This data is unavailable, and in survey data it is
unreliable. It is unreasonable to expect an individual to have the ability to recall the
frequency of daily injection for a long period of time. When a behaviour becomes an integral
part of your life, the frequency any given day begins to blur, particularly when many users do
not have the luxury of consistent dependable supply that they can build a “lifestyle” around.
3.

Recent Dental Procedures
This is applicable to both PWID and non-IDUs. Dental procedures may result in cuts

within an individual’s mouth that allow bacteria to access the bloodstream. Patients with
periodontal (gum) disease are at risk of bacteremia from brushing their teeth (Ito, 2006).
4.

Length of Drug Use
Length of IVDU would influence total exposure. An individual that has used

injection drugs a handful of times would be at a lower risk of exposure than an individual
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that has used injection drugs thousands of times, all else being equal. Knowing this
information would be helpful in distinguishing new and long-term drug users and what
influence length has on outcomes and the effects of covariates in the model.
5.

Drug Use Practices
As mentioned in sections 2.4 and 2.5, different drugs are associated with different risk

profiles and pathophysiologies. Compounds that are often homemade such as crystal
methamphetamine carry risks that differ based on the ingredients and sanitation standards of
the manufacturer and may influence the outcomes of a patient with IE.

5.4.2

Accuracy and Data Collection
There were variables that were collected with a great deal of precision. These include

age, sex, bacteria (MSSA, MRSA, Enterococci, Alpha-Hemolytic Streptococci, Coagulase
Negative Staphylococcus), valve affected (Aortic, Mitral, and Tricuspid), intracardiac device,
prosthetic valve, and fever. Age and biological sex are collected from the patients’ Ontario
Health Insurance Plan (OHIP) card. The bacteremia is recorded after having blood work
completed in the hospital. It is possible, however, that there were bacteria present that was
not included in the dataset, as the blood tests were not occurring with enough frequency to
ensure that any nosocomial bacteria did not present itself after the initial tests. Body
temperature as indicated by a binary fever variable is taken upon admission to the hospital
and regularly throughout a patient’s stay. This is hospital protocol and is thereby a reliable
statistic. The valve affected was determined via a transthoracic echocardiogram or, if
inconclusive, a transesophageal echocardiogram. It is possible that a vegetation was missed
upon examination by a physician after an echocardiogram, although there is no reason to
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believe there was a systemic bias present. Regarding prosthetic valves and intracardiac
devices, there would be medical records of the procedure, so it would be on the medical
charts.
Other variables may be less accurate and lead to bias in the results. These variables
include homelessness, intravenous drug use, HCV-positive, and HIV-positive.

1. Homelessness - The issue with this variable is the poor definition. Individuals that do
not have housing accommodations may be couch surfing among friends and relatives,
but are they homeless? Defining homelessness as an individual with no known
address may not include the patients that have their parents addresses on file,
although they do not have a home themselves per say. Also, as homelessness is not a
common question to ask, it is possible that it is disproportionately asked to admitted
users of intravenous drugs, and not asked among non-IDUs. This could present a
downward bias on non-IDUs.
2. Intravenous drug use - Many users of intravenous drugs are uncomfortable disclosing
the frequency of their use, or the fact that they use at all. I have personally
experienced situations where patients have tested positive for drugs that were not
prescribed, then denied ever having used them. The stigma surrounding intravenous
drugs, or illicit drugs in general, creates a dishonest environment where patients may
be inclined to tell the physician what they believe the physician would like to hear,
instead of the truth. Also, patients that are well presented or older may not be asked
about illicit drug use. Alternatively, the patients with clear indications of drug
addiction would be asked and that would be included in their charts. The clear
indications may include scarring, abscesses, malnutrition, poor hygiene, or any
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stereotypical characterization of those with drug addictions. This may also create a
bias as those with clear indications of drug use may be the only ones being asked
whether they are currently using injection drugs.
3.

HIV- and HCV-positive: The cases of HIV/HCV in the dataset were confirmed by
blood testing, although as mentioned in the Data and Methods section, 190 of the 378
patients were “unclear” for HIV. Among these patients, we have no way to confirm
whether these variables were determined based on the inquiry by a physician or if
each patient had their blood draws tested for HIV/HCV.

5.5 Generalizability
This dataset is unique in its proportion of PWID. While there are other communities
around North America, such as in Vancouver and pockets of larger American urban centers,
where there are large numbers of PWID, the incidence of infective endocarditis may not be
dominated by PWID in those cities. There would, however, be large populations of PWID in
these places that would be comparable to the PWID sample in London, Ontario. The
information on the variables that do and do not significantly influence survival among PWID
is generalizable to other PWID with similar drug cultures, particularly referring to the use of
crystal methamphetamine.
While drugs like cocaine and heroin use plants that are grown outside of North
America, crystal methamphetamine can be produced locally (Shukla, 2012). This, in
addition to the abundant supply from abroad and the relative cost-effectiveness in terms of
the effects produced by consuming the drug, it would be unsurprising to see the findings of
this research become increasingly generalizable to communities in the coming decades.
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5.6 Strengths
The major strengths of this dataset and analysis included reliability/accuracy of the
data, comprehensiveness and richness of variables to choose, and size. Working with PWID
is inherently difficult, as many biases present themselves. For example, as mentioned in the
previous section, recall bias makes pertinent variables like drug use frequency
unfeasible. This rich dataset overcomes this issue by relying solely on the observations and
testing results that were recorded by medical doctors. Although there are issues with missing
data, the quality and accuracy of the data is excellent relative to recall. This was the main
reason for using this dataset to answer these questions.
This dataset is reliable and comprehensive, and although the list of strengths is not
quite as long as the limitations, the magnitude of each strength is substantial. Observational
data is never perfect, but large dataset and statistical theory allow researchers to circumvent
this issue to some extent, given that the actual data you are working with is
accurate. Although there may have been situations where the physician asked the patient a
question, such as, “do you use injection drugs”, and then recorded the answer based on what
the patient says. This is more of an issue with Hepatitis-C and HIV response bias, although
having tested positive previously in a hospital setting would have made it into the charts and
therefore into the dataset. The physicians are interested in providing the best treatment for
patients, and if there was any question regarding the honesty of a patient, the physician
would be inclined to perform tests to determine for themselves rather than take the patients
word for it. This was shown in a study by Shah et al (2015) whereby immigrant stroke
patients with a language barrier showed more favourable health outcomes because the
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language barrier prevented physicians from asking patients, which introduces response bias,
and instead relied solely on medical testing. “Differences in quality of care may have arisen
because of language barriers: the healthcare team may have sought more intensive evaluation
of patients with whom their communication was impeded” (Shah et al, 2015). While not
perfectly analogous, the takeaway is that if physicians are unable to reliably ask the patient,
or the patient is unable to communicate well to the physician, the physician would be more
inclined to perform tests and find out for themselves.
The dataset that was utilized for this research is large in terms of both participants and
variables and the number of PWID. This increased the power to detect effects even when
using a PWID-only subgroup, which is rarely found within the endocarditis literature.
These three reasons: reliability/accuracy, comprehensiveness, and size make this
dataset optimal as a starting point for infective endocarditis in this local
environment. Despite these strengths, there is still much more room for improvement.

5.7 Future Directions
As a study based on historical hospital chart records, there are inherent limitations
which would be optimal to overcome for future research. Further studies should incorporate
time-dependent covariates such as date and time data for the occurrence of each independent
event with examples including sepsis and leaving against medical advice. This would answer
additional questions pertaining to what causes these dangerous outcomes to occur. This was
not the case and as such, our analysis will assume that the events occurred upon admission
which is not necessarily true (some of the patients acquired endocarditis in the hospital, not
before admission). Time-dependent covariates would also influence the survival analysis
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results and may provide more clarity as to which variables increase the hazards of death
among patients with IE.
Regarding the outcomes that were measured in this study, a very important and
interesting future direction for research would be to incorporate drug-related
data. Determining which drugs were consumed, how often they were consumed, the method
by which they were consumed, the environment they were consumed in, and the duration of
lifetime consumption. These drug variables would provide very informative insights and
may provide opportunities to target advice to the specific subpopulations that are most
greatly affected.
Since this research was conducted, a safe injection site has been introduced to
London, Ontario. Using the data collected for this research and contrasting it with data
collected since the inception of the safe injection site may provide some insights regarding
the effectiveness of such measures and whether the injection site is benefiting the community
at large. This may also influence the willingness for other cities throughout Canada to
participate in harm reduction, as infectious diseases among PWID are extremely costly to
manage and it is difficult to do so due to recurrence rates, at least with infective endocarditis.
London, Ontario tends to draw older populations and retirees from central Ontario.
The aging population that is commonly mentioned in academic literature refers to a young
population that ages, not an aging population that relocates to a new region, thereby causing
it to age. A future direction for research should include age-matched samples to ensure that
comparability between the younger PWID populations can exist and it is not a matter of sick,
older individuals moving to London and skewing the analysis.
Lastly, there should be a national database that collects and stores information
pertaining to PWID, or the population in general, that permits comparative analysis between
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cities and provinces. The generalizability is difficult to assess because of the lack of national
data available in Canada. Coordinating initiatives that gather health data at the federal level
may assist smaller regions in recognizing other areas that have similar issues, facilitating a
collaboration to improve outcomes among those afflicted with infectious diseases across the
country.

5.8 Conclusions
The most significant contribution made by this research is highlighting the magnitude
of the public health issues that face London, Ontario regarding PWID. With regards to IE,
we found the incidence to be rising among both PWID and non-IDUs. Univariate models
demonstrated a non-significant mortality risk difference between PWID and non-IDU,
despite the substantial (24.4 years, 95% C.I. 21.7 to 27.0) difference in ages between the two
populations. Multivariable analyses demonstrated that in the total group, injection drugs
(HR: 2.50, 95% C.I. 1.41 to 4.34), age (HR: 1.03 per year, 95% C.I. 1.01 to 1.05), MRSA
infection (HR: 3.23, 95% C.I. 1.79 to 5.84) and MSSA (HR:1.74, 95% C.I. 1.05 to 2.87)
infection were shown to be significantly associated with all-cause mortality. PWID-only
subgroups showed a significant hazard only with coinfections, specifically patients that were
HIV-positive (3.62, 95% C.I. 1.45 to 9.04) and/or HCV-positive (0.52, 95% C.I 0.30 to 0.93).
With the ongoing epidemic of drug non-prescribed drug misuse that is found throughout the
developed world, more efforts are required to reduce the incidence and impact of IE among
PWID.
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Appendices
Tables, figures, and outputs can be found below. For tables and figures, the captions are all
found below their respective items.

Table 1: Definition of Major and Minor Criteria. Extracted with permission from Li et
al (2000).
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Table 2: Clinical criteria for infective endocarditis. Extracted with permission by Li et
al (2000).
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Table 3: Population and incidence data for London, ON.

Using data from Statistics Canada (population: population totals for London,
Ontario) and medical chart data (IDU, nonIDU, and Total_Cases), the number
of per 100 000 person-years (PersonYears: population / 100 000) was
calculated, then used to find incidence rate per 100 000 person-years (Rate:
total cases / 100 000 person-years).

Variable

Description

Significance

Age

Age of patient at onset of firstepisode IE

Average patient age has been
increasing (currently > 70) and PWID
tend to have a much younger patient
age which may influence patient
outcomes

Sex

The patient’s sex (M/F)

Men are disproportionately affected
by infective endocarditis

Unstable housing indicator (Y/N)

Unstable and unsanitary living
conditions may influence immune
function

Homeless
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All-cause mortality

This is the outcome of interest in the
survival analysis

Native
Valve IE

IE present on an innate heart valve

This represents most infective
endocarditis cases

Intracardiac
Device

Includes prosthetic valves and any
medical devices found in the heart

May be particularly susceptible to
adherence by bacteria

Vegetation
Location

Mitral valve IE is most common in
the population at large and the
Aortic, Mitral, Pulmonic, Tricuspid,
majority of Tricuspid valve IE is
and any combination of the two
found among persons who inject
drugs.

Death

Bilateral

Vegetations present on both the left
(Aortic and/or Mitral) and right
(Tricuspid and/or pulmonic) sides
of the heart

Indicating a rally severe form of
infective endocarditis

Microbiology

MRSA, MSSA, Coagulase
Negative Staphylococcus, AlphaHemolytic Streptococcus,
Enterococcus, Beta-Hemolytic
Streptococcus, Gram-Negative
Aerobic Bacilli, Fungus, Negative,
Other

Bacteria groups formed in
consultation with Dr. Silverman,
Chair of Infectious Diseases at SJHC,
based on their treatment, where they
originate within the body, and
virulence (infectiousness)

Positive for HIV

HIV+ patients with low CD4 cell
count are also at a higher risk of
mortality from IE

HCV

Positive for Hepatitis C Virus

Liver disease caused by HCV may be
exacerbated by IE and lead to
increased mortality (Zignego et al,
2012)

Infections

Skin and Soft Tissue Infection,
Bone or Joint Infection, and
Respiratory Infection

Suggest a compromised immune
function and may place an individual
at a greater risk of further infection

Septic
Shock

Patient experiencing Sepsis in
response to an infection

Closely related to mortality among
patients with IE (Olmos et al, 2012)

Fever

Patient presenting a fever upon
admission into the hospital

A body temperature greater than
38°C, seen in ~90% of cases (Cahill,
2015)

HIV
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Leaving
AMA

Abandoning treatment at the
hospital against the opinion of
physicians

discontinuation of treatment may be
associated with poor health outcomes

Surgery

Patient received surgical
intervention to treat their IE

May improve prognosis following a
diagnosis of IE, although not
everyone is able to receive surgery

Table 4: Variables used to differentiate baseline characteristics between the total group,
PWID, and non-IDU patients in the dataset.

Figure 4: Long acting Hydromorph Contin after being drawn through a 25-gauge
syringe (unfiltered). Used with permission by Laura Ball.
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1

Figure 5: Long acting Hydromorph contin being drawn through a 25-gauge syringe
(filtered). Used with permission by Laura Ball.

2

Figure 6: a dodged bar plot showing incidence of infective endocarditis for PWID
and non-IDU patients.

3

The next section includes outputs from Kaplan-Meier and Cox Proportional Hazards
survival analyses and calculations to estimate prevalence. Each caption may be found
above the respective output.
Output 1: Results for Kaplan-Meier survival analysis demonstrating the probability
of survival over each time period in days for non-IDU.

4

Output 2: Results for Kaplan-Meier survival analysis demonstrating the probability
of survival over each time period in days for PWID.

5

Output 3: Results for Cox Proportional Hazards Model survival analysis for the
Full model.

6

Output 4: Results for cox proportional hazard survival analysis using PWID-only
data.

7

Output 5: Output for cox proportional hazard model using non-IDU-only data.
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Equation 1: Calculations for SMR estimation.
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